Notis Global (NGBL) 10-K 27 Nov 19 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Nov. 26, 2019	Jun. 30, 2017
Document And Entity Information
Entity Registrant Name	Notis Global, Inc.
Entity Central Index Key	0001547996
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Interactive Data Current	No
Entity Current Reporting Status	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 1,993,849
Entity Common Stock, Shares Outstanding		10,000,000,000
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2017

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Current assets
Cash	$ 90,466	$ 23,967
Accounts receivable, net	80,000
Inventory, net	84,210
Capitalized agricultural costs	394,903	160,131
Prepaid expenses and other current assets	35,840	92,976
Assets of discontinued operations	2,492	2,522
Total current assets	687,911	279,596
Property and equipment, net	6,344,983	6,712,369
Total assets	7,032,894	6,991,965
Current liabilities
Accounts payable	7,837,124	6,009,827
Accrued expenses	8,087,362	2,187,393
Accounts payable and accrued expenses - related parties	594,701	727,893
Liabilities of discontinued operations	1,022,553	1,020,127
Current portion of notes payable, net	4,191,657	3,367,478
Notes payable - related parties	289,866	289,866
Convertible notes payable, net	19,471,454	8,645,442
Convertible notes payable, - related parties	105,000	105,000
Due on demand note	312,431
Share Restriction Liability	60,374
Option liability	299,965
Derivative Liability	113,636,474	15,635,947
Warrant Liability	3,528,602	14,430
Total current liabilities	159,437,563	38,003,403
Notes Payable, less current portion		4,093,272
Total liabilities	159,437,563	42,096,675
Commitments and contingencies (Note 13)
Stockholders' Deficit
Preferred stock, $0.001 par value: 10,000,000 authorized; 0 issued and outstanding as of December 31, 2017 and 2016, respectively
Common stock, $0.001 par value: 10,000,000,000 authorized, 10,000,000,000 and 9,942,223,868 issued and outstanding as of December 31, 2017 and 2016, respectively	10,000,000	9,942,224
Additional paid-in capital	45,344,302	46,606,283
Treasury stock		(1,209,600)
Accumulated deficit	(207,748,971)	(90,443,617)
Total stockholders' deficit	(152,404,669)	(35,104,710)
Total liabilities and stockholders' deficit	$ 7,032,894	$ 6,991,965

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	10,000,000,000	10,000,000,000
Common stock, shares issued	10,000,000,000	9,942,223,868
Common stock, shares outstanding	10,000,000,000	9,942,223,868

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Total revenue	$ 489,097	$ 261,835
Operating expenses
Cost of revenues	516,546	463,315
General and administrative	5,033,339	9,944,022
Total operating expenses	5,549,885	10,407,337
Loss from operations	(5,060,788)	(10,145,502)
Other income (expense)
Interest expense, net	(21,044,042)	(6,066,598)
Change in fair value of derivative liabilities	(90,219,268)	(33,271,611)
Change in fair value of warrant liability	(237,120)	998,764
Gain on sale of interest in subsidiary		630,571
Loss on sale of rights and assets		(32,300)
Gain on debt forgiveness		(486,857)
Loss on failed business combination	(1,001,520)
Gain on extinguishment of debt		29,646,079
Other income (expense)	265,776	(65,468)
Total other expense	(112,236,174)	(7,673,706)
Loss from continuing operations	(117,296,962)	(17,819,208)
Discontinued operations
Income (loss) from discontinued operations	(8,392)	87,638
Loss before provision for income taxes	(117,305,354)	(17,731,570)
Provision for income taxes
Net loss	$ (117,305,354)	$ (17,731,570)
Loss per share attributable to common stockholders
Basic and diluted loss per share - continuing operations	$ (0.01)	$ (0.01)
Basic and diluted loss per share from discontinued operations	0	0
Basic and diluted loss per share	$ (0.01)	$ (0.01)
Weighted average shares outstanding
Basic and diluted	9,969,661,904	4,364,487,739
Other comprehensive loss
Net loss	$ (117,305,354)	$ (17,731,570)
Realized loss on discontinued operations		(187,154)
Comprehensive loss	(117,305,354)	(17,918,724)
Revenue [Member]
Total revenue	489,097	253,835
Service Revenue [Member]
Total revenue		$ 8,000

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Deficit - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	Total
Balance at Dec. 31, 2015		$ 240,972	$ (1,209,600)	$ 42,600,089	$ (72,524,893)	$ (193,755)	$ (31,087,187)
Balance, shares at Dec. 31, 2015		240,971,727	(60,000)
Sale of common stock		$ 851		15,149			16,000
Sale of common stock, shares		851,063
Stock-based compensation		$ 28,779		780,645			809,424
Stock-based compensation, shares		28,778,831
Investor contribution				324,754			324,754
Issuance of shares to consultants		$ 144,042		(47,252)			96,790
Issuance of shares to consultants, shares		144,042,308
Share cancelation		$ (1,634)		(485,223)			(486,857)
Share cancelation, shares		(1,633,652)
Conversions of convertible notes payable		$ 9,529,214					9,529,214
Conversions of convertible notes payable, shares		9,529,213,591
Gain on extinguishment of debt				3,418,121			3,418,121
Unrealized gain from marketable securities						193,755	193,755
Realized gain from marketable securities					(187,154)		(187,154)
Net income loss					(17,731,570)		(17,731,570)
Balance at Dec. 31, 2016		$ 9,942,224	$ (1,209,600)	46,606,283	(90,443,617)		(35,104,710)
Balance, shares at Dec. 31, 2016		9,942,223,868	(60,000)
Common stock issued for settlement of liabilities		$ 2,000		(2,000)
Common stock issued for settlement of liabilities, shares		2,000,000
Stock-based compensation		$ 17,076		$ 1,209,600	(1,223,216)		3,460
Stock-based compensation, shares		17,076,132		60,000
Conversions of convertible notes payable		$ 38,700		$ (36,765)			1,935
Conversions of convertible notes payable, shares		38,700,000
Net income loss					(117,305,354)		(117,305,354)
Balance at Dec. 31, 2017		$ 10,000,000		$ 45,344,302	$ (207,748,971)		$ (152,404,669)
Balance, shares at Dec. 31, 2017		10,000,000,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities
Net loss	$ (117,305,354)	$ (17,731,570)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	367,386	17,362
Provisions and allowances		120,841
Gain on debt forgiveness		(486,857)
Inventory valuation reserve		(5,000)
Change in fair value of derivative liability	90,219,268	33,271,611
Change in fair value of warrant liability	237,120	(998,764)
Change in fair value of option liability	40
Amortization of debt discount	4,080,199	4,162,769
Financing costs	6,574,761	581,817
Note principal increase upon default	4,601,289
Loss on failed business combination	1,001,520
Gain on extinguishment of debt		(29,646,079)
Stock based compensation	631,777	906,214
Changes in operating assets and liabilities:
Accounts receivable	(80,000)
Inventory	(84,210)	68,889
Capitalized agricultural costs	(234,772)	(160,131)
Prepaid expenses and other current assets	57,136	62,452
Advances for machinery		(310,725)
Deferred costs		76,000
Accounts payable	2,582,850	4,024,890
Other accrued expenses	5,899,969	707,611
Accrued expenses - related parties	(133,192)	1,786,928
Customer deposits		7,486
Net cash used in operating activities	(1,584,213)	(3,552,099)
Changes related to discontinued operations	2,456	(17,858)
Cash flows from investing activities
Payments made for investment in PCH	(588,063)
Issuance of note receivable		(10,000)
Repayment of note receivable		19,159
Proceeds received for sale of rights and assets		(30,000)
Construction in progress		(617,207)
Net cash used in investing activities	(588,063)	(638,048)
Cash flows from financing activities
Proceeds from issuance of notes payable	95,527	1,453,599
Payments on notes payable	(74,492)	(509,461)
Proceeds from issuance of demand loan	312,431
Exercise of employee stock options		16,000
Proceeds from issuance of convertible notes payable, net of fees	2,266,400	3,166,500
Payments on convertible notes payable	(363,547)
Proceeds from issuance of convertible notes payable - related party, net		52,500
Net cash provided by financing activities	2,236,319	4,179,138
Net change in cash and cash equivalents	66,499	(28,867)
Cash, beginning of year	23,967	52,834
Cash, end of year	90,466	23,967
Supplemental disclosures of cash flow information:
Cash paid for interest	237,902	38,595
Cash paid for income tax
Non- cash investing and financing activities:
Common stock issued upon debt conversion	38,700	12,947,334
Account payable assigned to note payable - related party		292,366
Account payable assigned to convertible note payable - related party		50,000
Account payable assigned to convertible notes payable	679,022	72,500
Account payable assigned to note payable	72,500
Issuance of warrants in connection with convertible debentures	3,009,034
Exchange of notes payable and accrued interest to convertible notes	3,966,199	753,122
Exchange of convertible notes payable and accrued interest to convertible notes		5,970,910
Advances on machinery paid directly by lender		161,401
OID - notes payable	12,759	239,496
OID - convertible notes payable		157,487
Convertible notes payable assigned to notes payable		1,431,401
Cancellation of notes payable for land		208,605
Debt discount additions for convertible notes	1,206,498	3,615,351
Debt discount additions for notes payable
Exchange of notes payable to related party to convertible notes payable to related party		2,500
Investor contribution		324,754
Unrealized gain on marketable securities		6,601
Common stock issued for settlements	2,000
Treasury stock	1,209,600
Share Restriction Liability	$ 12

Business Organization, Nature o

Business Organization, Nature of Operations	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Organization, Nature of Operations	NOTE 1 – BUSINESS ORGANIZATION, NATURE OF OPERATIONS Business Description Notis Global, Inc. (formerly Medbox, Inc.), which is incorporated in the state of Nevada (the “Company”), provides specialized services to the hemp and marijuana industry, distributes hemp product processed by contractual partners and through December 31, 2017, owned independently and through affiliates, real property and licenses that it leased and assigned or sublicensed to partner cultivators and operators in return for a percentage of revenues or profits from sales and operations (Note 5). Prior to 2016, through its consulting services, the Company worked with clients who sought to enter the medical and cultivation marijuana markets in those states where approved. In 2015, the Company expanded into hemp cultivation with the acquisition of a 320 acre farm (the “Farm”) in Colorado by the Company’s wholly-owned subsidiary, EWSD I, LLC dba Shi Farms (“EWSD”). The Farm was operated by an independent farming partner until the relationship was terminated in May 2016 (Note 3). In addition, through its wholly-owned subsidiary, Vaporfection International, Inc. (“VII”), the Company sold a line of vaporizer and accessory products online and through distribution partners. On March 28, 2016, the Company sold the assets of VII and exited the vaporizer and accessory business. As of December 31, 2016, the Company was headquartered in Los Angeles, California. As of the date of filing of this Annual Report, the Company was headquartered in Red Bank, New Jersey. Effective January 28, 2016, the Company changed its legal corporate name from Medbox, Inc., to Notis Global, Inc. The name change was effected through a parent/subsidiary short-form merger pursuant to Section 92A.180 of the Nevada Revised Statutes. Notis Global, Inc., the Company’s wholly-owned Nevada subsidiary formed solely for the purpose of the name change, was merged with and into the Company, with Notis Global, Inc. as the surviving entity. The merger had the effect of amending the Company’s Articles of Incorporation to reflect the new legal name of the Company. There were no other changes to the Company’s Articles of Incorporation. The Company’s Board of Directors (the “Board”) approved the name-change merger. Notis Global, Inc., operates the business directly and through the utilization of three primary operating subsidiaries, as follows: ● EWSD I, LLC, a Delaware limited liability company that owns property in Colorado. ● Pueblo Agriculture Supply and Equipment, LLC, a Delaware limited liability company that was established to own extraction equipment. ● Shi Cooperative, LLC, a Colorado limited liability company that contracts with third-party farmers to cultivate hemp in, among other areas, Colorado, Nevada, and Oklahoma. ● San Diego Sunrise, LLC, a California corporation to hold San Diego, California dispensary operations. (As of June 30, 2016, the Company sold its interest in San Diego Sunrise, LLC; see Note 5.) ● Prescription Vending Machines, Inc., a California corporation, d/b/a Medicine Dispensing Systems in the State of California (“MDS”), which previously distributed our Medbox product and provided related consulting services. ● Vaporfection International, Inc., a Florida corporation through which we distributed our medical vaporizing products and accessories. (All the assets of which were sold during the three months ended March 31, 2016). (See Note 6) ● Medbox Property Investments, Inc., a California corporation specializing in real property acquisitions and leases for dispensaries and cultivation centers. This corporation currently owns no real property. ● Vaporfection International, Inc., a Florida corporation through which we distributed our medical vaporizing products and accessories. (All the assets of which were sold during the three months ended March 31, 2016). During December of 2016, the Board and management completed a strategic shift and completely exited the vapor and medical cannabis dispensing line. (See Note 11) On April 15, 2016, at a special meeting of the stockholders of the Company, the stockholders of the Company holding a majority of the total shares of outstanding common stock (the “Common Stock”) of the Company voted to amend the Company’s Articles of Incorporation to increase the number of authorized shares of Common Stock from 400,000,000 to 10,000,000,000 (the “Certificate of Amendment”). The Certificate of Amendment was filed with the Nevada Secretary of State and was declared effective on April 18, 2016.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Going Concern The Consolidated Financial Statements were prepared on a going concern basis. The going concern basis assumes that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business. During the year ended December 31, 2017, the Company had a net loss from operations of approximately $117.3 million, negative cash flow from operations of $1.58 million and negative working capital of $158.7 million. During the year ended December 31, 2016, the Company had a net loss of approximately $17.7 million, negative cash flow from operations of $3.6 million and negative working capital of $37.7 million. The Company will need to raise capital in order to fund its operations. As of the date of this filing, the Company is in default on all notes outstanding. The Company is unable to predict the outcome of these matters; however, legal action taken by the Company’s lenders could have a material adverse effect on the financial condition, results of operations and/or cash flows of the Company and its ability to raise funds in the future. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the issuance of these financial statements. The ability to continue as a going concern is dependent on the Company’s ability to raise additional capital and implement its business plan. The Consolidated Financial Statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Management’s plans include: The Company expects that EWSD, which owns the 320 acre Farm in Pueblo, Colorado, will generate recurring revenues for the Company through farming hemp, extracting and selling CBD oil, and collecting fees from production related to extracting CBD oil for other farmers, while controlling the full production cycle to ensure consistent quality. Lastly, management is actively seeking additional financing over the next few months to fund operations. The Company will continue to execute on its business model by attempting to raise additional capital through the sales of debt or equity securities or other means. However, there is no guarantee that such financing will be available on terms acceptable to the Company, or at all. It is uncertain whether the Company can obtain financing to fund operating deficits until profitability is achieved. This need may be adversely impacted by: unavailability of financing, uncertain market conditions, the success of the crop growing season, the demand for CBD oil, the ability of the Company to obtain financing for the equipment and labor needed to cultivate hemp and extract the CBD oil, and adverse operating results. The outcome of these matters cannot be predicted at this time. On May 24, 2016, the Company received a notice from the OTC Markets Group Inc. (“OTC Markets”) that the Company’s bid price was below $0.01 and that the Company did not meet the Standards for Continued Eligibility for OTCQB pursuant to OTC Markets’ Standards. If the bid price did not close at or above $0.01 for ten consecutive trading days by November 20, 2016, the Company would be moved to the OTC Pink ® ® ® ® Principles of Consolidation The Consolidated Financial Statements include the accounts of Notis Global, Inc. and its wholly-owned subsidiaries, as named in Note 1 above. All intercompany transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Critical accounting estimates are estimates for which (a) the nature of the estimate is material due to the levels of subjectivity and judgment necessary to account for highly uncertain matters or the susceptibility of such matters to change and (b) the impact of the estimate on financial condition or operating performance is material. The Company’s critical accounting estimates and assumptions affecting the financial statements were: (i) Assumption as a going concern (ii) Fair value of long-lived assets: (iii) Valuation allowance for deferred tax assets (iv) Estimates and assumptions used in valuation of equity instruments These significant accounting estimates or assumptions bear the risk of change due to the fact that there are uncertainties attached to these estimates or assumptions, and certain estimates or assumptions are difficult to measure or value. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates. Discontinued Operations US GAAP requires the results of operations of a component of an equity that either has been disposed of or is classified as held for sale to be reported as discontinued operations in the consolidated financial statements if the sale or disposition represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results . Concentrations of Credit Risk The Company maintains cash balances at several financial institutions that are insured by the Federal Deposit Insurance Corporation up to $250,000. The Company has not experienced any losses in such accounts and periodically evaluates the credit worthiness of the financial institutions and has determined the credit exposure to be negligible. Fair Value of Financial Instruments Pursuant to ASC No. 825, Financial Instruments Embedded derivative – The Company’s convertible notes payable include embedded features that require bifurcation due to a reset provision and are accounted for as a separate embedded derivative (see Note 7). The Company estimated the fair value of the conversion feature derivatives embedded in the convertible debentures based on a Monte Carlo Simulation model (“MCS”). The MCS model was used to simulate the stock price of the Company from the valuation date through to the maturity date of the related debenture and to better estimate the fair value of the derivative liability due to the complex nature of the convertible debentures and embedded instruments. Management believes that the use of the MCS model compared to the Black-Scholes-Merton model as previously used would provide a better estimate of the fair value of these instruments The Company valued these embedded derivatives using a “with-and-without method,” where the value of the Convertible Debentures including the embedded derivatives, is defined as the “with”, and the value of the Convertible Debentures excluding the embedded derivatives, is defined as the “without.” This method estimates the value of the embedded derivatives by observing the difference between the value of the Convertible Debentures with the embedded derivatives and the value of the Convertible Debentures without the embedded derivatives. The Company believes the “with-and-without method” results in a measurement that is more representative of the fair value of the embedded derivatives. For each simulation path, the Company used the Geometric Brownian Motion (“GBM”) model to determine future stock prices at the maturity date. The inputs utilized in the application of the GBM model included a starting stock price, an expected term of each debenture remaining from the valuation date to maturity, an estimated volatility, and a risk-free rate. For the years ended December 31, 2017 and 2016, the Company estimated the fair value of the conversion feature derivatives embedded in the convertible debentures based on an internally calculated adjustment to the MCS valuation determined at December 31, 2016. This adjustment took into consideration the changes in the assumptions, such as market value and expected volatility of the Common Stock, and the discount rate used in the December 31, 2016, valuation as compared to December 31, 2017. Warrants The Company reexamined the determination made as of December 31, 2016, that it did not have sufficient authorized shares available for all of their outstanding warrants to be classified in equity at December 31, 2017, and concluded there still were insufficient authorized shares (Note 7). Therefore, the Company recognized a warrant liability as of December 31, 2017. The Company estimated the fair value of the warrant liability based on the Black-Scholes-Merton model. The key assumptions used consist of the price of the Company’s stock, a risk-free interest rate based on the average yield of a one- to three-year Treasury note (based on remaining term of the related warrants), and expected volatility of the Common Stock over the remaining life of the warrants. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly. Level 3 Significant unobservable inputs that cannot be corroborated by market data. The assets or liabilities’ fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of the relevant assets and liabilities that are measured at fair value on a recurring basis: December 31, 2017 Total Quoted Prices Quoted Prices for Similar Assets or Liabilities in Active Significant Unobservable Inputs Warrant liability 3,528,602 - - 3,528,602 Option liability 299,965 - - 299,965 Derivative liability 113,636,474 - - 113,636,474 Total liabilities $ 117,465,041 $ - $ - $ 117,465,041 December 31, 2016 Total Quoted Prices Quoted Prices Significant Unobservable Inputs Warrant liability 14,430 - - 14,430 Derivative liability 15,635,947 - - 15,635,947 Total liabilities $ 15,650,377 $ - $ - $ 15,650,377 The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis: For the year ended December 31, 2017 Total January 1, 2017 15,650,377 Initial recognition of conversion feature 7,781,259 Initial recognition of warrant liability 3,277,052 Initial recognition of option liability 299,925 Change in fair value of conversion feature 90,219,268 Change in fair value of warrant liability 237,120 Change in fair value of option liability 40 Ending Balance, December 31, 2017 $ 117,465,041 For the year ended December 31, 2016 Total January 1, 2016 $ 20,186,594 Initial recognition of conversion feature 581,817 Change in fair value of conversion feature 33,271,611 Gain on extinguishment of debt (37,464,075 ) Change in fair value of liability (918,969 ) Unrealized loss on marketable securities (6,601 ) December 31, 2016 15,650,377 Revenue Recognition Revenues from Cannabidiol oil product The Company recognizes revenue from the sale of Cannabidiol oil products (“CBD oil”) upon shipment, when title passes, and when collectability is reasonably assured. Cost of Revenue Cost of revenue consists primarily of expenses associated with the delivery and distribution of the Company’s products and services. Under the Company’s prior business model, the Company only began capitalizing costs when it obtained a license and a site for operation of a customer dispensary or cultivation center. The previously capitalized costs are charged to cost of revenue in the same period that the associated revenue is earned. In the case where it is determined that previously inventoried costs are in excess of the projected net realizable value of the sale of the licenses, then the excess cost above net realizable value is written off to cost of revenues. Cost of revenues also includes the rent expense on master leases held in the Company’s name, which are subleased to the Company’s operators. In addition, cost of revenue related to the Company’s vaporizer line of products consists of direct procurement cost of the products along with costs associated with order fulfillment, shipping, inventory storage and inventory management costs. Cash and cash equivalents The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of December 31, 2017 and 2016, the Company held no cash equivalents. The Company’s policy is to place its cash with high credit quality financial instruments and institutions and limit the amounts invested with any one financial institution or in any type of instrument. Deposits held with banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash. Accounts Receivable and Allowances Accounts receivable are recorded at the invoiced amount and are not interest bearing. The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. The Company makes ongoing assumptions relating to the collectability of its accounts receivable in its calculation of the allowance for doubtful accounts. In determining the amount of the allowance, the Company makes judgments about the creditworthiness of customers based on ongoing credit evaluations and assesses current economic trends affecting its customers that might impact the level of credit losses in the future and result in different rates of bad debts than previously seen. The Company also considers its historical level of credit losses. As of December 31, 2017 and 2016, there was an allowance for doubtful accounts of $0. Inventory The Company utilizes lower of standard cost or net realizable value method. During the years ended December 31, 2017 and 2016, the Company recorded an impairment of $0 and $32,300 respectively, that was recorded to cost of revenues. Capitalized agricultural costs Capitalized agricultural costs consists of pre-harvest agricultural costs, including irrigation, fertilization, seeding, laboring, other ongoing crop and land maintenance activities and work-in-progress activities. All capitalized agricultural costs are accumulated and capitalized as incurred. The Company has reflected the capitalized agriculture costs as a current asset as the growing cycle of the crops are estimated to be six months to a year. Basic and Diluted Net Income/Loss Per Share Basic net loss per share of Common Stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of Common Stock outstanding during the period. Diluted net loss per share of Common Stock is determined using the weighted-average number of shares of Common Stock outstanding during the period, adjusted for the dilutive effect of Common Stock equivalents. In periods when losses are reported, which is the case for the years ended December 31, 2017 and 2016 presented in these Consolidated Financial Statements, the weighted-average number of shares of Common Stock outstanding excludes Common Stock equivalents because their inclusion would be anti-dilutive. The Company had the following Common Stock equivalents at December 31, 2017 and 2016: December 31, 2017 December 31, 2016 Warrants 11,765,757,748 69,757,748 Options 1,000,000,000 - Convertible notes – related party 10,500,000 10,500,000 Convertible notes 465,782,195,939 114,808,810,010 Totals 478,558,453,687 114,889,067,758 Property and Equipment Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The Company uses accelerated depreciation methods for tax purposes where appropriate. The estimated useful lives for significant property and equipment categories are as follows: Vehicles 5 years Furniture and Fixtures 3 - 5 years Office equipment 3 years Machinery 2 years Buildings 10 - 39 years Income Taxes The Company accounts for income taxes under the asset and liability method. The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the Consolidated Financial Statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The components of the deferred tax assets and liabilities are classified as current and non-current based on their characteristics. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. In addition, the Company’s management performs an evaluation of all uncertain income tax positions taken or expected to be taken in the course of preparing the Company’s income tax returns to determine whether the income tax positions meet a “more likely than not” standard of being sustained under examination by the applicable taxing authorities. This evaluation is required to be performed for all open tax years, as defined by the various statutes of limitations, for federal and state purposes. Commitments and Contingencies Certain conditions may exist as of the date the Consolidated Financial Statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management and its legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Consolidated Financial Statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed. The Company accrues all legal costs expected to be incurred per event. For legal matters covered by insurance, the Company accrues all legal costs expected to be incurred per event up to the amount of the deductible. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers,” which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for annual reporting periods for public business entities beginning after December 15, 2017, including interim periods within that reporting period. The new standard permits the use of either the retrospective or cumulative effect transition method. The Company is currently evaluating the effect that ASU 2014-09 will have on its financial statements and related disclosures. The Company has not yet selected a transition method nor determined the effect of the standard on its ongoing financial reporting. On July 22, 2015, the FASB issued a new standard that requires entities to measure most inventory “at the lower of cost and net realizable value,” thereby simplifying the current guidance under which an entity must measure inventory at the lower of cost or market. The new standard will not apply to inventories that are measured by using either the last-in, first-out (LIFO) method or the retail inventory method. The new standard will be effective for fiscal years beginning after December 15, 2016, and interim periods in fiscal years beginning after December 15, 2016. The adoption did not have a material effect on its financial position or results of operations or cash flows. In April 2015, the FASB issued a new standard that requires an entity to determine whether a cloud computing arrangement contains a software license. If the arrangement contains a software license, the entity would account for the fees related to the software license element in a manner consistent with how the acquisition of other software licenses is accounted for. If the arrangement does not contain a software license, the customer would account for the arrangement as a service contract. The new standard will be effective for fiscal years beginning after December 15, 2015, and interim periods in fiscal years beginning after December 15, 2016. The adoption did not have a material effect on its financial position or results of operations or cash flows. In February 2016, the FASB issued “Leases (Topic 842)” (ASU 2016-02). This update amends leasing accounting requirements. The most significant change will result in the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under current guidance. The new guidance will also require significant additional disclosures about the amount, timing, and uncertainty of cash flows from leases. ASU 2016-02 is effective for fiscal years and interim periods beginning after December 15, 2018, which for the Company is December 31, 2018, the first day of its 2019 fiscal year. Upon adoption, entities are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. Early adoption is permitted, and a number of optional practical expedients may be elected to simplify the impact of adoption. The Company is currently evaluating the impact of adopting this guidance. The overall impact is that assets and liabilities arising from leases are expected to increase based on the present value of remaining estimated lease payments at the time of adoption. In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting Compensation – Stock Compensation In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842).” Under ASU 2016-02, lessees will, among other things, require lessees to recognize a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. ASU 2016-02 does not significantly change lease accounting requirements applicable to lessors; however, certain changes were made to align, where necessary, lessor accounting with the lessee accounting model and ASC Topic 606, “Revenue from Contracts with Customers.” ASU 2016-02 will be effective for us on January 1, 2019 and initially required transition using a modified retrospective approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. In July 2018, the FASB issued ASU 2018-11 , “Leases (Topic 842) - Targeted Improvements,” which, among other things, provides an additional transition method that would allow entities to not apply the guidance in ASU 2016-02 in the comparative periods presented in the financial statements and instead recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. In December 2018, the FASB also issued ASU 2018-20, “Leases (Topic 842) - Narrow-Scope Improvements for Lessors,” which provides for certain policy elections and changes lessor accounting for sales and similar taxes and certain lessor costs. As of January 1, 2019, the Company adopted ASU 2016-02 and has recorded a right-of-use asset and lease liability on the balance sheet for its operating leases. We elected to apply certain practical expedients provided under ASU 2016-02 whereby we will not reassess(i) whether any expired or existing contracts are or contain leases, (ii) the lease classification for any expired or existing leases and (iii) initial direct costs for any existing leases. We also do not expect to apply the recognition requirements of ASU 2016-02 to any short-term leases (as defined by related accounting guidance). We expect to account for lease and non-lease components separately because such amounts are readily determinable under our lease contracts and because we expect this election will result in a lower impact on our balance sheet. In October 2016, the FASB issued ASU 2016-16, “Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other than Inventory”, which eliminates the exception that prohibits the recognition of current and deferred income tax effects for intra-entity transfers of assets other than inventory until the asset has been sold to an outside party. The updated guidance is effective for annual periods beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption of the update is permitted. The Company is currently evaluating the impact of the new standard. In April 2016, the FASB issued ASU No. 2016-10, “Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing” (topic 606). In March 2016, the FASB issued ASU No. 2016-08, “Revenue from Contracts with Customers: Principal versus Agent Considerations (Reporting Revenue Gross versus Net)” (topic 606). These amendments provide additional clarification and implementation guidance on the previously issued ASU 2014-09, “Revenue from Contracts with Customers”. The amendments in ASU 2016-10 provide clarifying guidance on materiality of performance obligations; evaluating distinct performance obligations; treatment of shipping and handling costs; and determining whether an entity’s promise to grant a license provides a customer with either a right to use an entity’s intellectual property or a right to access an entity’s intellectual property. The amendments in ASU 2016-08 clarify how an entity should identify the specified good or service for the principal versus agent evaluation and how it should apply the control principle to certain types of arrangements. The adoption of ASU 2016-10 and ASU 2016-08 is to coincide with an entity’s adoption of ASU 2014-09, which we adopted for interim and annual reporting periods beginning after December 15, 2017. The Company is currently evaluating the impact of adopting this guidance. In May 2016, the FASB issued ASU No. 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients”, which narrowly amended the revenue recognition guidance regarding collectability, noncash consideration, presentation of sales tax and transition and is effective during the same period as ASU 2014-09. The Company is currently evaluating the impact of adopting this guidance. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments” (“ASU 2016-15”). ASU 2016-15 will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017. The new standard will require adoption on a retrospective basis unless it is impracticable to apply, in which case it would be required to apply the amendments prospectively as of the earliest date practicable. The Company is currently evaluating the impact of adopting this guidance. In October 2016, the FASB issued ASU 2016-16, “Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other than Inventory”, which eliminates the exception that prohibits the recognition of current and deferred income tax effects for intra-entity transfers of assets other than inventory until the asset has been sold to an outside party. The updated guidance is effective for annual periods beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption of the update is permitted. The Company is currently evaluating the impact of the new standard. In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230)”, requiring that the statement of cash flows explain the change in the total cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. This guidance is effective for fiscal years, and interim reporting periods therein, beginning after December 15, 2017 with early adoption permitted. The provisions of this guidance are to be applied using a retrospective approach which requires application of the guidance for all periods presented. The Company is currently evaluating the impact of adopting this guidance. In July 2017, the FASB issued ASU 2017-11, “Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception”. Part I of this update addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. Part II of this update addresses the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable noncontrolling interests. The amendments in Part II of this update do not have an accounting effect. This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. The Company is currently evaluating the impact of adopting this guidance. In May 2017, the FASB issued ASU 2017-09, “Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting,” which provides guidance about which changes to the terms or conditions of a sha

Asset Acquisition

Asset Acquisition	12 Months Ended
	Dec. 31, 2017
Business Combinations [Abstract]
Asset Acquisition	NOTE 3 – ASSET ACQUISITION Farming Agreement On December 18, 2015, the Company and EWSD entered into a Farming Agreement (the “Farming Agreement”) with Whole Hemp Company LLC (“Whole Hemp” now known as “Folium Biosciences, LLC”), pursuant to which Folium Biosciences would manufacture products from hemp and cannabis crops it would grow on EWSD farmland, and the Company would build greenhouses for such activities up to an aggregate size of 200,000 square feet. Folium Biosciences would pay all preapproved costs of such construction on or before September 30, 2017 as partial consideration for a revocable license to use the greenhouses and a separate 10 acre plot of EWSD farmland (the “10 Acres”). EWSD would retain ownership of the greenhouses. For the first growing season commencing October 1, 2016, the Company would receive a percentage of gross sales of all Folium Bioscience’s products on a monthly basis, and the Company’s share would increase incrementally based on the extent of crops planted on EWSD farmland according to a mutually agreed schedule. In addition, the Company would receive 50% of Folium Biosciences’ gross profits from the farming activities on the 10 Acres. The Company planned to recognize all revenue from the Farming Agreement at the net amount received when it has been earned and determined collectable. Pursuant to the Farming Agreement, the Company also granted Folium Biosciences a warrant to purchase 4,000,000 shares of Common Stock at an exercise price of $0.50 per share, exercisable at any time within five years. The warrants were valued at $76,000, using the Black-Scholes-Merton model, with key valuation assumptions used that consist of the price of shares of Common Stock at settlement date, a risk-free interest rate based on the average yield of a five-year Treasury note and expected volatility of shares of Common Stock, all as of the measurement date. The fair value of the warrants is included in deferred costs and will be recognized over the life of the Farming Agreement. Due to the termination of the Farming and Growers Distribution Agreements, as discussed below, as of September 30, 2016, this amount has been fully amortized. On March 11, 2016, the Company and EWSD entered into a First Amended and Restated Farming Agreement with Whole Hemp, amending, and restating in certain respects the Farming Agreement. The First Amended and Restated Farming Agreement clarifies that EWSD, rather than the Company, would be responsible for the building of greenhouses to be utilized by Whole Hemp for growing hemp and cannabis crops pursuant to the agreement, and that EWSD would be the recipient of all payments by Whole Hemp (including all revenue sharing arrangements) under the agreement. On or about May 7, 2016, the Company determined that Folium Biosciences was in default of the Farming Agreement, principally because it had abandoned its obligation to provide farming activities under the First Amended and Restated Farming Agreement. On May 13, 2016, EWSD notified Folium Biosciences of its defaults under the First Amended and Restated Farming Agreement and EWSD’s election to terminate the First Amended and Restated Farming Agreement. By its terms, the First Amended and Restated Farming Agreement may be terminated at any time by either party, if the other party was in material breach of any obligation under the First Amended and Restated Farming Agreement, which breach continued uncured for 30 days following written notice thereof. On June 1, 2016, a complaint was filed by Whole Hemp on this matter, naming the Company and EWSD, as defendants. See Whole Hemp Complaint, below. Growers’ Distributor Agreement On December 18, 2015, the Company also entered into a Growers’ Agent Agreement with Folium Biosciences, which was amended on March 11, 2016, to change the name of the agreement to Growers’ Distributor Agreement, (“Distributor Agreement”) and to clarify some terms. Pursuant to the Distributor Agreement, the Company would provide marketing, sales, and related services on behalf of Folium Biosciences in connection with the sale of its Cannabidiol oil product (“CBD oil”), from which the Company would receive a percentage of gross revenues (other than the sale of such product generated from the EWSD 10 Acres and the Folium Biosciences 40 acre plot subject to the Farming Agreement). The Growers’ Agent Agreement was effective until September 30, 2025. The Company would sell the product on behalf of Folium Biosciences on a commission basis. The Company may not act as agent of any other grower, distributor, or manufacturer of the same product unless such other party agrees. On March 11, 2016, the Company and EWSD entered into a First Amended and Restated Grower’s Distributor Agreement with Whole Hemp, amending and restating in certain respects the Grower’s Agent Agreement, including by substituting EWSD as a party in place of the Company. Because the Company believes Folium Biosciences is in default, principally because it had abandoned its obligation to provide farming activities under the First Amended and Restated Farming Agreement since May 7, 2016, EWSD notified Whole Hemp on May 13, 2016 of its election to terminate the Restated Grower’s Distributor Agreement. By its terms, the Restated Grower’s Distributor Agreement could be terminated at any time by either party, if the other party was in material breach of any obligation under the Restated Grower’s Distributor Agreement, which breach continued uncured for 30 days following written notice thereof. Whole Hemp Complaint A complaint was filed by Whole Hemp Company, LLC (“Whole Hemp”) on June 1, 2016, naming the Company and EWSD (collectively, the “Company Defendants”), as defendants in Pueblo County, CO district court. The complaint alleges five causes of action against the Company Defendants: misappropriation of trade secrets, civil theft, intentional interference with prospective business advantage, civil conspiracy, and breach of contract. All claims concern contracts between Whole Hemp and the Company Defendants for the Farming Agreement and the Distributor Agreement. The court entered an ex parte On August 12, 2016, the court ordered that all of Whole Hemp’s plants in the Company Defendants’ possession be destroyed, which occurred by August 24, 2016, at which time the temporary restraining order was dissolved and the parties were expected to file a motion to dismiss the district court action. In light of the Whole Hemp plants all being destroyed pursuant to the court order, the Company has immediately expensed all Capitalized agricultural costs as of June 30, 2016, as all costs as of that date related to Whole Hemp plants. The Company Defendants commenced arbitration in Denver, CO on August 2, 2016, seeking injunctive relief and alleging breaches of the contracts between the parties. Whole Hemp filed an Answer and counterclaims on September 6, 2016, asserting similar allegations that were asserted to the court. On September 30, 2016, the arbitrator held an initial status conference and agreed to allow the Company Defendants to file a motion to dismiss some or all of Whole Hemp’s claims by no later than October 28, 2016. The parties were also ordered to make initial disclosures of relevant documents and persons with knowledge of relevant information by October 21, 2016. On or about July 19, 2016, EWSD initiated arbitration before JAMS (Case ID: 18657). Effective June 20, 2017, as a result of a mediation held in Colorado, the parties entered into a Confidential Settlement and Mutual Release Agreement (the “Release Agreement”), pursuant to which the parties dismissed with prejudice all of their respective claims or counterclaims against each other, as asserted in the Arbitration, and mutually released each other from all claims. The Release Agreement specifically provides that neither its execution nor implementation is, or will be deemed to be or construed as, an admission by any party of any liability, act, or matter.

Inventory and Capitalized Agric

Inventory and Capitalized Agricultural Costs	12 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Inventory and Capitalized Agricultural Costs	NOTE 4 – INVENTORY AND CAPITALIZED AGRICULTURAL COSTS Inventories and capitalized agricultural costs are generally kept for a short period of time. Finished goods Growing costs Biomass Raw materials Inventory at December 31, 2017 and 2016 consisted of the following: December 31, 2017 December 31, 2016 Finished goods $ 84,210 $ — Growing crops and biomass 394,903 160,131 Total inventory, net $ 479,113 $ 160,131 The Company recorded a markdown of $0 and $32,300 during the years ended December 31, 2017 and 2016, respectively.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Property and Equipment	NOTE 5 – PROPERTY AND EQUIPMENT Property and equipment at December 31, 2017 and 2016 consists of: Property and Equipment December 31, 2017 December 31, 2016 Advances - 472,126 Land 4,945,000 4,945,000 Construction in progress - 1,241,380 Buildings and structures 1,300,630 59,250 Machinery 497,011 21,600 6,742,641 6,739,356 Less accumulated depreciation (397,658 ) (26,988 ) Property and equipment, net $ 6,344,983 $ 6,712,368 Depreciation expense for the years ended December 31, 2017 and 2016, was $367,385 and $ 17,363

PCH Investment

PCH Investment	12 Months Ended
	Dec. 31, 2017
Investments Schedule [Abstract]
PCH Investment	NOTE 6 – PCH INVESTMENT Effective as of March 21, 2017, through a series of related transactions, Notis intended to acquire, indirectly, an aggregate of 459,999 of the then-issued and outstanding shares of capital stock (the “PCH To-Be-Purchased Shares”) of PCH Investment Group, Inc., a California corporation (“PCH”) for a proposed purchase price of $300,000 in cash and the proposed issuance of shares of Common Stock. The PCH To-Be-Purchased Shares represented 51% of the outstanding capital stock of PCH. In connection with the Company’s then-intended acquisition of the PCH To-Be-Purchased Shares, the Company (or its affiliates) was also to be granted an indirect option to acquire the remaining 49% (the “PCH Optioned Shares”) of the capital stock of PCH. The option was to expire on February 10, 2019 (the “PCH Optioned Shares Expiry Date”). Located in San Diego, California, PCH was a management services business that focused on the management of cannabis production and manufacturing businesses. On November 1, 2016, PCH entered into a Management Services Agreement (the “PCH Management Agreement”) with California Cannabis Group (“CalCan”) and Devilish Delights, Inc. (“DDI”), both of which then were California nonprofit corporations in the cannabis production and manufacturing business (“their business”). CalCan and Mr. Pyatt represented that CalCan was then licensed by the City of San Diego, California, to cultivate cannabis and manufacture cannabis products, as well as to sell, at wholesale, the cultivated and manufactured products at wholesale to legally operated medical marijuana dispensaries. The PCH Management Agreement provided that PCH was responsible for the day-to-day operations and business activities of their business. In that context, PCH was to be responsible for the payment of all operating expenses of their business (including the rent and related expenditures for CalCan and DDI) from the revenue generated by their business, or on an out-of- pocket basis if the revenue should be insufficient. In exchange for PCH’s services and payment obligations, PCH was to be entitled to 75% of the gross profits of their business. The PCH Management Agreement did not provide for any gross profit milestone during its first 12 months; thereafter, it provided for an annual $8 million gross profit milestone, with any amount in excess thereof to be carried forward to the next annual period. In the event that, during any annual period, the gross profit thereunder was less than $8 million (including any carry-forward amounts), then, on a one- time basis, PCH would have been permitted to carry-forward such deficit to the following annual period. If, in that following annual period, the gross profit was to have exceeded $6 million, then PCH would have been entitled to an additional “one-time basis” carry-forward of a subsequent deficit. The term of the PCH Management Agreement was for five years, subject to two extensions, each for an additional five-year period, in all cases subject to earlier termination for an uncured material breach by PCH of its obligations thereunder. Mr. Pyatt, the Company’s then- current Chief Operating Officer and Senior Vice President, Government Affairs, was also then a member of the Board of Directors of CalCan and DDI. Pursuant to a Securities Purchase Agreement, that was made and entered into as of March 16, 2017 (five days before the presumed closing of the transaction; the “SPA”), “PASE” was to have acquired the PCH To-Be-Purchased Shares from the three PCH shareholders: (i) Mystic, LLC, a California limited liability company that Mr. Goh, the Company’s then-Chief Executive Officer, formed and controlled for his investments in cannabis projects, (ii) Mr. Pyatt, and (iii) Mr. Kaller, then the general manager of PCH (collectively, the “PCH Shareholders”). As a condition to the Lender entering into the Note Purchase Agreement and the PCH-Related Note (both as noted below) and providing any additional funding to the Company in connection with its intended acquisition of the PCH To-Be-Purchased Shares, the Board ratified the forms of employment agreements for Mr. Goh, as the Company’s then-Chief Executive Officer, and for Mr. Pyatt, as the Company’s then-prospective President. If the agreements became effective, and following the second anniversary thereof, the terms were to have become “at- will.” In addition to payment of a base salary, the agreements provided for certain cash, option, and equity bonuses, in each case to become subject both to each individual and to the Company meeting certain performance goals to be acknowledged by them and to be approved by a disinterested majority of the Board. Due to the nature of the above-described intended transaction, and the related parties involved with PCH, the Company formed a special committee of its Board to consider all of the aspects thereof, as well as the related financing proposed to be provided by the Lender. The special committee consisted of three of the four directors: Ambassador Ned L. Siegel, Mitch Lowe, and Manual Flores. In the context of the special committee’s charge, it engaged an otherwise independent investment banking firm (the “Banker”) to analyze the potential acquisition of the PCH To-Be-Purchased Shares through the SPA (noted above) and the Stock Purchase Option Agreement (the “PCH Option Agreement”; the parties to which are PASE, PCH, the PCH Shareholders, as noted below), the related financing agreements (all as noted below), other related business and financial arrangements, and the above-referenced employment agreements. After the Banker completed its full review of those agreements and its own competitive analysis, it provided its opinion that the consideration to be paid in connection with the acquisition of the PCH To- Be-Purchased Shares and the terms of the PCH-Related Note were fair to the Company from a financial point of view. Following the Banker’s presentation of its analysis and opinion, and the special committee’s own analysis, the special committee unanimously recommended to the full Board that all of such transactions should be approved and that the Company could consummate the acquisition of the PCH To-Be-Purchased Shares, accept the option to acquire the PCH Optioned Shares, enter into the PCH-Related Note, the documents ancillary thereto, and the Employment Agreements. In connection with the Company’s intended acquisition of the PCH To-Be-Purchased Shares and the Company’s intended option to acquire the PCH Optioned Shares, PASE, EWSD, PCH, and the Company entered into a Convertible Note Purchase Agreement (the “Note Purchase Agreement”) with a third-party lender (the “PCH Lender”). Concurrently, PASE and the Company (with EWSD and PCH as co-obligors) entered into a related 10% Senior Secured Convertible Promissory Note (the “PCH-Related Note”) in favor of the PCH Lender. The initial principal sum under the PCH-Related Note was $1,000,000 and it bears interest at the rate of 10% per annum. Principal and interest are subject to certain conversion rights in favor of the PCH Lender. So long as any principal is outstanding or any interest remains accrued, but unpaid, at any time and from time to time, at the option of the PCH Lender, any or all of such amounts may be converted into shares of Common Stock. Notwithstanding such conversion right, and except in the circumstance described in the next sentence, the PCH Lender may not exercise its conversion rights if, in so doing, it would then own more than 4.99% of the Company’s issued and outstanding shares of Common Stock. However, upon not less than 61 days’ notice, the PCH Lender may increase its limitation percentage to a maximum of 9.99%. The PCH Lender’s conversion price is fixed at $0.0001 per share. Principal and accrued interest may be pre-paid from time to time or at any time, subject to 10 days’ written notice to the PCH Lender. Any prepayment of principal or interest shall be increased to be at the rate of 130% of the amount so to be prepaid and, during the 10-day notice period, the PCH Lender may exercise its conversion rights in respect of any or all of the amounts otherwise to be prepaid. In a series of other loan transactions prior to the intended closing of the acquisition of the PCH To-Be-Purchased Shares, a different third party lender (the “Ongoing Lender”) had lent to the Company, in five separate tranches, an aggregate amount of approximately $414,000 (the “Pre-acquisition Loans”), that, in turn, the Company lent to PCH to use for its working capital obligations. Upon the purported closing of the acquisition of the PCH To-Be-Purchased Shares and, pursuant to the terms of the PCH-Related Note, the PCH Lender lent to the Company (i) approximately $86,000, that, in turn, the Company lent to PCH to use for its additional working capital obligations, (ii) $300,000 for the purported acquisition of the PCH To-Be-Purchased Shares, and (iii) $90,000 for various transaction-related fees and expenses. Immediately subsequent to the closing of the purported acquisition of the PCH To-Be-Purchased Shares, the PCH Lender lent to the Company (x) approximately $170,000 for the Company’s operational obligations and (y) approximately $114,000 for the Company partially to repay an equivalent amount of the Pre-acquisition Loans. In connection with the Pre-acquisition Loans and the PCH-Related Note, the makers and co-obligors thereof entered into an Amended and Restated Security and Pledge Agreement in favor of the Lender, pursuant to which such parties, jointly and severally, granted to the Lender a security interest in all, or substantially all, of their respective property. Further, PCH entered into a Guarantee in favor of the PCH Lender in respect of the other parties’ obligations under the PCH-Related Note. PCH’s obligation to the PCH Lender under these agreements is limited to a maximum of $500,000. As of the intended closing of the acquisition of the PCH To-Be-Purchased Shares, the Company paid $300,000 to the PCH Shareholders. If that transaction had closed, the Company would also have become obligated to issue to the PCH Shareholders 1,500,000,000 shares (the “Purchase Price Shares”) of Common Stock. That number of issuable shares was to be subject to certain provisions detailed in the PCH-Related Note, which are summarized herein. Notwithstanding the number of issuable shares referenced above, the number of issued Purchase Price Shares was to have been equal to 15% of the then-issued and outstanding shares of Common Stock at the time that the Company exercised its option to acquire the PCH Optioned Shares under the PCH Option Agreement. Further, in the event that the Company were to have issued additional equity securities prior to the date on which it in fact had issued the Purchase Price Shares at a price per share that was less than the value referenced above, the PCH Shareholders would have been entitled to “full ratchet” anti-dilution protection in the calculation of the number of Purchase Price Shares to be issued (with the exception of a recapitalization by the Lender to reduce the Company’s overall dilution). If the Company did not exercise the intended option to acquire the PCH Optioned Shares prior to PCH Optioned Shares Expiry Date, the PCH Shareholders would have had the right to reacquire the PCH To-Be-Purchased Shares from the Company for the same cash consideration ($300,000) that was to have been paid to them for those shares. Further, if the Company were to be in default of its material obligations under the SPA, or if PASE were the subject of any bankruptcy proceedings, then the PCH Shareholders have the same reacquisition rights noted in the preceding sentence. Pursuant the PCH Option Agreement, PASE was granted the option to purchase all 49%, but not less than all 49%, of the PCH Optioned Shares. The exercise price for the PCH Optioned Shares is an amount equivalent to five times PCH’s “EBITDA” for the 12-calendar month period, on a look-back basis, that concludes on the date of exercise of the Option, less $10 (which was the purchase price of the option). The calculation of the 12-month EBITDA was to be determined by PASE’s (or its) then-currently engaged independent auditors. If the Company were to exercise the option prior to the first anniversary of the closing of the acquisition of the PCH To-Be-Purchased Shares, then the exercise price for the PCH Optioned Shares was to be based on the EBITDA for the entire 12-calendar month period that commenced with the effective date of the PCH Option Agreement. PCH Investment Group, Inc. – San Diego Project Termination On March 27, 2017, the Company filed a Current Report on Form 8-K to announce the above-described series of events. Subsequently, it became clear to the Company that the PCH Parties failed to make key closing deliveries, including, without limitation, actual transfer of the PCH To-Be-Purchased Shares, the PCH Lease (as defined below) and related marijuana licenses. Thereafter, the parties entered into litigation and eventual settlement as described below. The Settlement Agreement and Mutual General Release The Company, PACE, and EWSD (collectively, the “Notis Parties”) and PCH, Messrs. Pyatt, Kaller, and Goh (solely in connection with his status as an equity holder of PCH, collectively, the “PCH Individuals”; and, with PCH, collectively, the “PCH Parties”) entered into a Settlement Agreement and Mutual General Release, with an effective date of August 16, 2017 (the “Settlement Agreement”), inter alia 1. One or both of the PCH Lender and the Ongoing Lender (collectively, the “Notis Lenders”) and PCH have certain disagreements in respect of their respective rights and obligations in and related to certain of the SPA and related documents; 2. Some or all of the Notis Parties and the Notis Lenders, on the one hand, and PCH and the PCH Individuals, on the other hand, have certain disagreements in respect of the conduct of PCH’s business; 3. Some or all of the Notis Parties and PCH have certain disagreements in respect of the ownership and possessory right of certain of the furniture and equipment utilized by PCH on its own behalf or on behalf of others in respect of the conduct of PCH’s business located at 9212 Mira Este Court, San Diego, California (the location for the “PCH Lease”); 4. The Notis Parties and the PCH Parties have certain disagreements in respect of their respective rights and obligations in and related to the SPA; 5. PCH and Trava LLC, a Florida limited liability company and a material lender to PCH, have certain disagreements in respect of their respective rights and obligations in and related to the PCH / Trava Master Service Agreement (as defined in the Settlement Agreement); 6. Notis and Mr. Pyatt have certain disagreements in respect of their respective rights and obligations in and related to the Pyatt Employment Agreement (as defined in the Settlement Agreement), as manifested in part by Mr. Pyatt’s filing of the Pyatt Labor Complaint (as defined in the Settlement Agreement); 7. The Notis Parties and the PCH Parties have certain disagreements in respect of the Notis Parties and the PCH Parties’ respective conduct in connection with PCH’s rights and obligations in and related to the PCH / SDO Master Service Agreement (as defined in the Settlement Agreement); 8. The Notis Lenders and PCH have certain disagreements in respect of the PCH’s conduct in connection with PCH’s rights and obligation in and related to certain of the Notis Financing Documents (as defined in the Settlement Agreement); 9. The Notis Lenders and PCH have certain disagreements in respect of the ownership and possessory rights of certain of the Equipment (as defined in the Settlement Agreement); and 10. Some or all of the Notis Parties and the PCH Individuals, among others, have certain disagreements in respect of the operation of the PCH Shareholder/Buy-Sell Agreement (as defined in the Settlement Agreement). See, also, Change of Officers and Directors In connection with the PCH investment, the Company recorded $1,001,520 as a loss in connection with the failed and unconsummated business combination. The $1,001,520 is the amount the Company invested in the PCH transaction.

Convertible Notes Payable and D

Convertible Notes Payable and Derivative Liability	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Convertible Notes Payable and Derivative Liability	NOTE 7 – CONVERTIBLE NOTES PAYABLE AND DERIVATIVE LIABILITY Convertible notes payable consists of: December 31, 2017 December 31, 2016 Investor #1 $ 15,198,404 $ 6,642,745 Investor #2 2,087,198 1,857,146 Investor #3 293,009 231,142 Investor #4 2,462,284 - Investor #5 300,000 - 20,340,895 8,731,033 Less discounts (869,441 ) (85,591 ) Plus premium - - Less current maturities 19,471,454 8,645,442 Convertible notes payable, net of current maturities $ - $ - Investor #1 During the year ended December 31, 2016 the Company issued 30 convertible notes to third-party lenders totaling $9,700,170. The Company received cash of $2,695,000 and original issue discounts of $119,737. The lender also paid $161,401 on advancements on fixed assets and consolidated principal and interest of $6,818,744. These convertible notes accrue interest at a rate of 10% per annum and mature with interest and principal both due between July 13, 2016 through September 9, 2017. This note is secured by the Company’s assets. The convertible notes convert at a fixed rate of $0.75 or a 49% to 40% discount with a lookback of 30 trading days. Due to the fact that these convertible notes have an option to convert at a variable amount, they are subject to derivative liability treatment. The Company has applied ASC 815, due to the potential for settlement in a variable quantity of shares. The conversion feature of Investor #1’s notes during the year ended December 31, 2016, gave rise to a derivative liability of $12,259,532, of which $1,952,380 were recorded as a debt discount. The debt discount is charged to accretion of debt discount and issuance cost ratably over the term of the convertible notes. $10,307,152 was recorded due to the consolidation of the principal and interest and was expense to loss on extinguishment. During the year ended December 31, 2016 Investor #1 converted $802,926 of principal into 4,374,651,437 shares of Common Stock. During the year ended December 31, 2016 Investor #1 converted $5,188,643 of principal and $686,827 of interest into the consolidation loan disclosed in respect of Investor #1 and Investor #3 elsewhere in these notes. The Company has recorded $36,071,697 gain on extinguishment. During the year ended December 31, 2017 the Company issued 29 convertible notes to third-party lenders totaling $1,529,297. The Company received cash of $1,066,400 and paid $413,457 from the PCH-Related Note. (See Note 6). These convertible notes accrue interest at a rate of 10% per annum and mature with interest and principal both due between February 3, 2017 through December 4, 2018. The notes convert at a fixed rate of $0.0001 or a 50% discount with a lookback of 30 trading days. Due to the fact that these convertible notes have an option to convert at a variable amount, they are subject to derivative liability treatment. The Company has applied ASC 815, due to the potential for settlement in a variable quantity of shares. The conversion feature of Investor #1’s convertible notes during the year ended December 31, 2017, gave rise to a derivative liability of $2,950,900. $1,036,301 which was recorded as a debt discount. The debt discount is charged to accretion of debt discount and issuance cost ratably over the term of the convertible note. During the year ended December 31, 2017 the Company went into default on all of Investor #1’s convertible notes. These notes now accrue interest at a rate of 24% per annum, a late fee of 18% on interest outstanding compounding quarterly and the principal increases by 50%-30%. The increase of principal of $3,698,710 was recorded to interest expense. Upon default, 18 promissory notes held by Investor #1 became convertible. The Company reclassed $3,691,199 from notes payable to convertible notes payable. During the year ended December 31, 2017, the Company repaid $250,000 in principal and $37,148 in interest. Investor #2 During the year ended December 31, 2016, the Company issued two convertible notes to third-party lenders totaling $278,000. The Company received cash of $235,000 and the lender paid $43,000 on behalf of the Company for vendor liabilities. These convertible notes accrue interest at a rate of 5% per annum and mature with interest and principal both due between July 13, 2016 through April 30, 2017. This note is secured by the Company’s assets. The convertible notes convert at a fixed rate of $0.75 or a 49% discount with a lookback of 20 trading days. Due to the fact that these convertible notes have an option to convert at a variable amount, they are subject to derivative liability treatment. The Company has applied ASC 815, due to the potential for settlement in a variable quantity of shares. The conversion feature of Investor #2’s convertible notes during the year ended December 31, 2016, gave rise to a derivative liability of $282,312, of which $265,917 was recorded as a debt discount. The debt discount is charged to accretion of debt discount and issuance cost ratably over the term of the convertible notes. $16,395 was above the face value of the convertibles notes and was recorded as interest expense. During the year ended December 31, 2017, the Company went into default on all of Investor #2’s convertible notes. These notes now accrue interest at a rate of 24% per annum and a late fee of 18% on interest outstanding compounding quarterly. The default caused a derivative expense of $549,535. Upon default, the promissory note held by Investor #2 became convertible. The Company reclassed $275,000 from notes payable to convertible notes payable. During the year ended December 31, 2016, Investor #2 converted $1,450,661 of principal and $38,002 of interest into 4,949,130,904 shares of Common Stock. During the year ended December 31, 2017, Investor #2 converted $1,935 of principal into 38,700,000 shares of Common Stock. At December 31, 2017, the Company was in default on all the convertible debentures with Investor #2. Investor #3 During the year ended December 31, 2016, the Company issued two convertible notes to third-party lenders totaling $282,500. The Company received cash of $236,500, original issue discounts of $34,750 and the lender paid $11,250 on behalf of the Company for vendor liabilities. These convertible notes accrue interest at a rate of 10% per annum and mature with interest and principal both due between September 14, 2016 through August 20, 2017. This note is secured by the Company’s assets. These notes are convertible upon default at a rate of $0.75 or a 49% discount with a lookback of 30 trading days. Due to the fact that these notes have an option to convert at a variable amount upon default, they are subject to derivative liability treatment. The Company has applied ASC 815, due to the potential for settlement in a variable quantity of shares. The conversion feature of Investor #3’s convertible notes during the year ended December 31, 2016, gave rise to a derivative liability of $672,335, of which $332,592 was recorded as a debt discount. The debt discount is charged to accretion of debt discount and issuance cost ratably over the term of the convertible notes. $339,743 was above the face value of the convertible notes and was recorded as interest expense. During the year ended December 31, 2016 Investor #3 converted $51,358 of principal into 205,431,250 shares of Common Stock. Investor #4 During the year ended December 31, 2017, the Company issued seven convertible notes to third-party lenders totaling $1,641,522. The Company received cash of $1,000,000 and paid $641,522 towards farm expenses. These convertible notes accrue interest at a rate of 10% per annum and mature with interest and principal both due between March 15, 2018 through November 09, 2018. This note is secured by the Company’s assets. The notes convert at a fixed rate of $0.0001 or a 50% discount with a lookback of 30 trading days. Due to the fact that these convertible notes have an option to convert at a variable amount, they are subject to derivative liability treatment. The Company has applied ASC 815, due to the potential for settlement in a variable quantity of shares. The conversion feature of Investor #4’s notes during the year ended December 31, 2017, gave rise to a derivative liability of $3,842,628. In addition, the Company issued warrants to purchase 10,000,000,000 shares of common stock. The warrant entitles the holder to purchase shares of Common Stock at a purchase price of $0.0001 per share for a period of four years from the issue date. The Company recorded a $2,979,231 debt discount relating to the warrants issued to the investor. The debt discounts are charged to accretion of debt discount and issuance cost ratably over the term of the convertible note. During the year ended December 31, 2017, the Company went into default on all of Investor #4 convertible notes. These notes now accrue interest at a rate of 24% per annum, a late fee of 18% on interest outstanding compounding quarterly and the principal increases by 50%. The increase of principal of $820,761 was recorded to interest expense. Investor #5 During the year ended December 31, 2017, the Company issued two convertible notes to third-party lenders totaling $200,000. The Company received cash of $200,000. These convertible notes accrue interest at a rate of 10% per annum and mature with interest and principal both due between April 27, 2018 through May 8, 2018. This note is secured by the Company’s assets. These notes are convertible upon default at a rate of $0.0001 or a 49% discount with a lookback of 30 trading days. Due to the fact that these convertible notes have an option to convert at a variable amount, they are subject to derivative liability treatment. The Company has applied ASC 815, due to the potential for settlement in a variable quantity of shares. The conversion feature of Investor #5’s convertible notes during the year ended December 31, 2017, gave rise to a derivative liability of $438,196, of which $170,198 was recorded as a debt discount. In addition, the Company issued warrants to purchase 200,000 shares of Common Stock. The warrant entitles the holder to purchase shares of Common Stock at a purchase price of $0.0001 per share for a period of four years from the issue date. The Company recorded a $29,802 debt discount relating to the warrants issued to the investor. The debt discounts are charged to accretion of debt discount and issuance cost ratably over the term of the convertible notes. During the year ended December 31, 2017, the Company went into default on all of Investor #4’s convertible notes. These notes now accrue interest at a rate of 24% per annum, a late fee of 18% on interest outstanding compounding quarterly and the principal increases by 50%. The increase of principal of $100,000 was recorded to interest expense. Related Party Financing One of the members of the Board entered into three separate subordinated convertible promissory notes convertible at $0.01 with the Company on March 4, 2016, March 10, 2016, and March 15, 2016, respectively, each in the principal amount of $25,000, for a total of $75,000. Also on March 15, 2016, another of the Company’s directors entered into a subordinated convertible promissory note convertible at $0.01 with the Company in the principal amount of $25,000, and two other of the Company’s directors each entered into a subordinated convertible promissory note convertible at $0.01 with the Company in the principal amount of $2,500. All of the foregoing convertible promissory notes have three year terms and an interest rate of 8% per annum. The debentures were evaluated to determine if the conversion feature fell within the guidance for derivative accounting, and as the debentures are convertible at a fixed conversion price, and do not include a reset provision to occur upon subsequent sales of securities at a price lower than the fixed conversion price, the Company concluded the conversion feature did not qualify as a derivative. In connection with their funding of the Notes (collectively, the “Board Notes”), the directors each received a warrant, exercisable for a period of three (3) years from the date of Board Notes, to purchase an amount of Common Stock equal to 50% of the principal sum under each of the Board Notes, at an exercise price equal to 200% of the applicable Conversion Price. The exercise price of the warrants is $0.02. The warrants were determined to have a fair value of $42,000, calculated with the Black-Scholes-Merton model, with the following key valuation assumptions: estimated term of three years, annual risk-free rate of 0.93%, and annualized expected volatility of 172%.

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Notes Payable	NOTE 8 – NOTES PAYABLE Notes payable consists of: December 31, 2017 December 31, 2016 Southwest Farms $ 3,536,279 $ 3,590,241 East West Secured Development 486,531 503,031 Investor #1 103,847 3,691,200 Investor #2 - 275,000 Investor #6 65,000 - 4,191,657 8,059,472 Less discounts - (598,721 ) Plus premium - - Subtotal notes payable 4,191,657 7,460,751 Less current maturities 4,191,657 3,367,479 Notes payable, net of current maturities $ - $ 4,093,272 Investor #1 During the year ended December 31, 2016, the Company issued 18 convertible notes to third-party lenders totaling $3,691,199. The Company received cash of $1,095,741, original issue discounts of $996,199 and the lender paid $145,000 on behalf of the Company for vendor liabilities. These convertible notes accrue interest at a rate between 5% to 10% per annum and mature with interest and principal both due between December 12, 2016 through November 18, 2017. This note is secured by the Company’s assets. These notes are convertible upon default at a rate of $0.75 or a 40% discount with a lookback of 20 trading days. Due to the fact that these notes have an option to convert at a variable amount upon default, they are subject to derivative liability treatment. The Company has applied ASC 815, due to the potential for settlement in a variable quantity of shares. The conversion feature of Investor #4’s notes during the year ended December 31, 2017, gave rise to a derivative liability of $390,967, of which $230,901 was recorded as a debt discount. The debt discount is charged to accretion of debt discount and issuance cost ratably over the term of the convertible note. $328,116 was above the face value of the note and was recorded as interest expense. During the year ended December 31, 2017, the Company issued 4 notes to third-party lenders totaling $103,847. The Company received cash of $95,527, original issue discounts of $819 and the lender paid $7,500 on behalf of the Company for vendor liabilities. These notes mature from May 2017 through August of 2017. During the year ended December 31, 2017, the Company went into default on all of Investor #1’s notes. The notes now accrue interest at a rate of 24% per annum. Upon default, 18 promissory notes held by Investor #1 became convertible. The Company reclassed $3,691,199 from notes payable to convertible notes payable. Investor #2 During the year ended December 31, 2017, the Company went into default on all of Investor #2’s notes. The notes now accrue interest at a rate of 24% per annum. Upon default, the promissory note held by Investor #2 became convertible. The Company reclassed $275,000 from notes payable to convertible notes payable. Investor #6 During the year ended December 31, 2017, the Company issued a promissory note to a vendor totaling $65,000 to settle an outstanding vendor liability. The Company recorded a gain of settlement of vendor liability of 82,776 that is included in other income. Investor #7 On April 6, 2016, the Company entered into a promissory note for $87,500, which was issued with a $2,500 premium, and bears interest at 0.0%. The proceeds were to be used by the Farm, to pay for water usage. Additionally, the Company issued 600,000 shares of its restricted common stock to the holder. The shares were valued at the market value of the common shares of the Company on the date of the issuance of the note. The payment terms called for $40,000 to be paid on or before April 21, 2016, $20,000 to be paid on or before May 6, 2016, and the final $27,500 to also be paid on or before May 6, 2016. The Note also allowed for the extension of the maturity date by 30 days, at the Company’s request, in exchange for an additional $2,500 payment. The note and the $2,500 extension payment were paid during July 2016. Related Party Financing Notes payable, related parties, consists of: December 31, 2017 December 31, 2016 Notes payable – related parties $ 289,866 $ 289,866 Less discounts — — $ 289,866 $ 289,866 On March 14, 2016, the Company issued Promissory Notes (the “March 2016 Directors Notes”), in the amount of $41,667, to a director in exchange for various amounts outstanding for fees and reimbursements incurred during the year ended December 31, 2015. The March 2016 Directors Notes are due on demand and bear interest at 8% until the March 2016 Directors’ Notes are paid in full. On June 14, 2016, the Company issued Promissory Notes (the “June 2016 Director’s Notes”), in the amount of $250,700, to all the directors in exchange for various amounts outstanding for fees and reimbursements incurred during December 2015 and April 2016. The June 2016 Director’s Notes have a term of six months and bear interest at 8% until the June 2016 Director’s Notes are paid in full. The June 2016 Director’s Notes were each issued with a warrant for 50% of the face amount of each June 2016 Director’s Note, with an exercise price of $0.01 and exercisable for three years. The warrants were determined to have a fair value of $12,000, calculated with the Black-Scholes-Merton model, with the following key valuation assumptions: estimated term of three years, annual risk-free rate of .93%, and annualized expected volatility of 172%. The $12,000 fair value was recognized as a debt discount and is being amortized over the six-month term of the June 2016 Directors Notes.

Stockholders' Deficit

Stockholders' Deficit	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Stockholders' Deficit	NOTE 9 – Stockholders’ Deficit Preferred Stock The Series A Preferred Stock has special voting rights when voting as a class with the Common Stock as follows: (i) the holders of Series A Preferred Stock shall have such number of votes as is determined by multiplying (a) the number of shares of Series A Preferred Stock held by such holder, by (b) the number of issued and outstanding shares of the Company’s Series A Preferred Stock and Common Stock (collectively, the “Common Stock”) on a Fully-Diluted Basis (as hereinafter defined), as of the record date for the vote, or, if no such record date is established, as of the date such vote is taken or any written consent of stockholders is solicited, and by (c) 0.00000025; and (ii) the holders of Common Stock shall have one vote per share of Common Stock held as of such date. “Fully-Diluted Basis” mean that the total number of issued and outstanding shares of Common Stock shall be calculated to include (a) the shares of Common Stock issuable upon exercise and/or conversion of all of the following securities (collectively, “Common Stock Equivalents”): all outstanding (a) securities convertible into or exchangeable for Common Stock, whether or not then convertible or exchangeable (collectively, “Convertible Securities”), (b) subscriptions, rights, options and warrants to purchase shares of Common Stock, whether or not then exercisable (collectively, “Options”), and (c) securities convertible into or exchangeable or exercisable for Options or Convertible Securities and any such underlying Options and/or Convertible Securities. As of December 31, 2017 and 2016, there were no shares of Series A Preferred Stock outstanding. Common Stock Our Articles of Incorporation authorize 10,000,000,000 shares of common stock. As of November 26, 2019, our Board has authorized the issuance of all of the shares of Common Stock, of which shares 9,982,923,868 are held of record or in street name by our stockholders. On January 20, 2017, the Company issued 2,000,000 shares of its restricted Common Stock to in connection with the settlement of the Crystal v. Medbox, Inc. During the year ended December 31, 2017 the Company issued 17,076,132 shares of Common Stock as compensation to a director. The Company recorded $50,098 as stock-based compensation expense. During the year ended December 31, 2016 the Company received $16,000 for the sale of 851,063 shares of Common Stock. During the year ended December 31, 2016 the Company issued 144,042,308 shares of Common Stock to consultants for services rendered. These shares had a fair value of 96,790. During the year ended December 31, 2016, $324,754 was contributed by a related party. During the year ended December 31, 2016 the Company issued 28,778,831 shares of Common Stock to employees for services rendered. These shares had a fair value of $809,424. During the year ended December 31, 2016 an investor cancelled 1,633,652 as part of the Derivative Settlements discussion below. For shares of Common Stock that were issued upon conversion of the convertible debentures during the years ended December 31, 2017 and 2016, see Note 7. Share-based awards, restricted stock and restricted stock units (“RSUs”) The Board resolved that, beginning with the fourth calendar quarter of 2015, the Company shall pay each member of the Board, who is not also then an employee of the Company, for each calendar quarter during which such member continues to serve on the Board, compensation in the amount of $15,000 in cash and 325,000 shares of Common Stock. The 975,000 shares issued to all the directors for the three months ended March 31, 2016 were valued at the market price of shares of Common Stock on March 31, 2016, for total compensation expense of $9,750. On March 31, 2016, the Board awarded the Chairman a cash bonus of approximately $89,000 and, 2,230,000 shares of Common Stock for his service in the three months ended March 31, 2016. The Board authorized grants of approximately 2,761,000 shares of Common Stock during the second quarter of 2016, which were valued at the market price of shares of Common Stock on date of grant, for total compensation expense of approximately $13,000. On June 8, 2016, the Board also awarded the Chairman a cash bonus of approximately $89,200 and 6,027,000 shares of Common Stock, valued at approximately $8,000. The Board also voted on June 8, 2016, to increase the shares available for grant under the 2014 Equity Incentive Plan to 125,000,000. A summary of the activity related to RSUs for the years ended December 31, 2017 and 2016 is presented below: Restricted stock units (RSUs) Total shares Grant date fair RSUs non-vested at January 1, 2017 7,142,856 $ 0.51 - $1.88 RSUs granted 250,975,000 $ 0.0002 - $0.0003 RSUs vested (258,117,856 ) $ 0.0002 - $1.88 RSUs forfeited - $ - RSUs non-vested December 31, 2017 - $ - Restricted stock units (RSUs) Total shares Grant date fair RSUs non-vested at January 1, 2016 152,823 $ 0.51 - $1.88 RSUs granted 14,285,714 $ 0.007 RSUs vested (7,295,681 ) $ 0.51- $1.88 RSUs forfeited - $ - RSUs non-vested December 31, 2016 7,142,856 $ 0.51 - $1.88 A summary of the expense related to restricted stock, RSUs and stock option awards for the year ended December 31, 2017 and 2016 is presented below: Year ended RSUs $ 50,293 Stock options 299,925 Total $ 350,218 Year ended RSUs $ 261,196 Common stock 539,246 Total $ 800,442 Warrant Activities The Company applied fair value accounting for all share-based payments awards. The fair value of each warrant granted is estimated on the date of grant using the Black-Scholes-Merton model. The assumptions used for warrants granted during the year ended December 31, 2017 and 2016 are as follows: December 31, 2017 December 31, 2016 Exercise price $ 5.54 - 0.0001 $ 0.02 Expected dividends 0 % 0 % Expected volatility 284.72% - 249.30 % 289.97 % Risk free interest rate 1.54% - 1.44 % 1.6 % Expected life of warrant 4 years 3 years The following is a summary of the Company’s warrant activity: Warrants Weighted Average Exercise Price Weighted Average Remaining Days Price Outstanding – December 31, 2015 43,161,222 $ 0.16 $ 2.77 Granted 22,595,859 0.04 3.00 Exercised - - - Forfeited/Cancelled - - - Outstanding – December 31, 2016 65,757,081 0.11 1.97 Granted 11,800,000,000 0.0001 4 Exercised - - - Forfeited/Cancelled (100,000,000 ) 0.001 - Outstanding and Exercisable – December 31, 2017 11,765,757,081 $ 0.0007 $ 3.23 At December 31, 2017, the aggregate intrinsic value of warrants outstanding and exercisable was $2,340,000 and $1,340,000, respectively. During the year ended December 31, 2017 and 2016, there were no warrants exercised. The Company adopted a sequencing policy that reclassifies contracts, with the exception of stock options, from equity to assets or liabilities for those with the earliest inception date first. Any future issuance of securities, as well as period-end reevaluations, will be evaluated as to reclassification as a liability under the sequencing policy of earliest inception date first until all of the convertible debentures are either converted or settled. For warrants issued in 2015, the Company determined that the warrants were properly classified in equity as there is no cash settlement provision and the warrants have a fixed exercise price and, therefore, result in an obligation to deliver a known number of shares. The Company reevaluated the warrants as of December 31, 2017 and determined that they did not have a sufficient number of authorized and unissued shares to settle all existing commitments, and the fair value of the warrants for which there was insufficient authorized shares, were reclassified out of equity to a liability. Under the sequencing policy, of the approximately 11,765,757,081 warrants outstanding at December 31, 2017. The fair value of these warrants was re-measured on December 31, 2017 using the Black-Scholes-Merton model, with key valuation assumptions used that consist of the price of the Company’s stock on December 31, 2017, a risk-free interest rate based on the average yield of a 1 or 4 year Treasury note and expected volatility of shares of Common Stock, resulting in the fair value for the Warrant liability of approximately $3,528,602. The resulting change in fair value of approximately $237,120 for the year ended December 31, 2017, was recognized as a loss in the Consolidated Statement of Comprehensive Income (loss). During the year ended December 31, 2017, a total of 10,200,000,000 warrants were issued with convertible notes payable (See Note 7 above). The warrants have a grant date fair value of $3,009,034, using the Black-Scholes-Merton model and the above assumptions. 5,000,000,000 shares vest upon the Company reaching $12 million in revenue. During the year ended December 31, 2017, a total of 1,600,000,000 warrants were issued for services. The warrants have a grant date fair value of $268,018 using the Black-Scholes-Merton model and the above assumptions. The following is a summary of the Company’s option activity: Warrants Weighted Average Exercise Price Weighted Average Remaining Days Price Outstanding – December 31, 2016 - - - Granted 1,000,000,000 $ 0.0001 5.00 Exercised - - - Forfeited/Cancelled - - - Outstanding and Exercisable – December 31, 2017 1,000,000,000 $ 0.0001 $ 4.59 At December 31, 2017 and 2016, the aggregate intrinsic value of options outstanding and exercisable was $200,000 and $0, respectively. Stock-based compensation for stock options has been recorded in the consolidated statements of operations and totaled $ 299,925 and $0, for the year ended December 31, 2017 and 2016, respectively. The following is a summary of the Company’s stock options granted during the year ended December 31, 2017: Options Value Purpose for Grant 1,000,000,000 $ 299,925 Service Rendered

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 10 – RELATED PARTY TRANSACTIONS During the first quarter of 2016, the Company issued three convertible notes to one of its directors in the aggregate principal amount of $75,000 and one convertible note to another of its directors in the aggregate principal amount of $25,000, plus a convertible note to each of its other to directors, in the amount of $2,500 each. In the second quarter of 2016, the Company issued promissory notes to all of the directors, in exchange for past unpaid cash bonuses, board compensation and expenses. See Note 8 for a description of these notes.

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2017
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	NOTE 11 – DISCONTINUED OPERATIONS Management deemed the vapor and medical cannabis dispensing line of operations discontinued in the 4th quarter of 2016. This determination was due to poor performance and decreasing gross profit of the Company businesses and resulted in an overall halt of operations of the Company in the 4th quarter of 2016. Upon analysis of the individual business lines, the Company’s newly formed special committee decided not to continue in the vapor and medical cannabis dispensing industries. On March 28, 2016, the Company sold the assets of the vapor subsidiary for $70,000. At the time of the asset disposal, it was disclosed as not a strategic shift in operations; however, with the inclusion of the medical cannabis dispensing operations, the definition of a strategic shift was met. One definition of a strategic shift is a disposal of “80 percent interest in one of two product lines that account for 40 percent of total revenue”. The disposal of both operations meets the definition of a strategic shift and should therefore be shown as discontinued operations in the Consolidated Financial Statements. The following subsidiaries of the Company qualify as discontinued operations: ● Prescription Vending Machines, Inc. ● Medbox Management Services, Inc. ● Medbox Rx, Inc. ● Vaporfection International, Inc. ● MJ Property Investments, Inc. The income (loss) from discontinued operations presented in the income statement for the year ended December 31, 2017 and 2016, consisted of the following: For the year ended December 31, 2017 2016 Revenue $ - $ 243,965 Revenue, related party - 99,946 Net revenue - 343,911 Cost of revenues - 99,411 Gross profit (loss) - 244,500 Operating expenses General and administrative 5,171 65,647 Total operating expenses 5,171 65,647 Loss from operations 5,171 178,853 Other income (expense) Interest expense, net (3,221 ) (8,858 ) Gain on sale of assets of subsidiary - 5,498 Loss on sale of rights and assets - (178,833 ) Loss on default settlement of a note - (168,092 ) Other-than-temporary impairment of Marketable securities - (16,010 ) Other income - 141,058 Total other income (expense) (3,221 ) (225,237 ) Net loss $ (8,392 ) $ (46,384 )

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 12 – INCOME TAXES The Company accounts for income taxes under FASB ASC 740-10, which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recorded based on the differences between the tax basis of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences. Deferred income taxes are provided for temporary differences arising from using the straight-line depreciation method for financial statement purposes and accelerated methods of depreciation for income taxes, including differences between book and tax for amortizing organization expenses. In addition, deferred income taxes are recognized for certain expense accruals, allowances and net operating loss carry forwards available to offset future taxable income, net of valuation allowances for potential expiration and other contingencies that could impact the Company’s ability to recognize the benefit. The Company is required to file federal and state income tax returns. Various taxing authorities may periodically audit the Company’s income tax returns. These audits would include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. Management has performed its evaluation of all other income tax positions taken on all open income tax returns and has determined that there were no positions taken that do not meet the “more likely than not” standard. Accordingly, there are no provisions for income taxes, penalties or interest receivable or payable relating to uncertain income tax provisions in the accompanying Consolidated Financial Statements. The Company is currently delinquent on filing its tax returns. From time to time, the Company may be subject to interest and penalties assessed by various taxing authorities. These amounts have historically been insignificant and are classified as other expenses when they occur. Deferred tax assets and liabilities result from temporary differences in the recognition of income and expense for tax and financial reporting purposes. Significant components of the Company’s deferred tax assets and liabilities are as follows at December 31: 2017 2016 Deferred tax assets: $ - $ - Customer deposits - - Deferred revenue - - Share based compensation 631,779 906,214 NOL carryforward 3,375,214 2,469,000 Total deferred tax asset 4,006,993 3,375,214 Deferred tax liabilities: Intangible asset amortization — 4,006,993 3,375,214 Less: Valuation allowance (4,006,993 ) (3,375,214 ) $ - $ - A valuation allowance has been recorded against the realizability of the net deferred tax asset such that no value is recorded for the asset in the accompanying Consolidated Financial Statements. The valuation allowance decreased $4,006,993 between the year ended December 31, 2017 and 2016. For the years ended December 31, 2017 and 2016, a reconciliation of the statutory rate and effective rate for the provisions for income taxes consists of the following: 2017 2016 Federal tax statutory rate 34.00 % 34.00 % State tax statutory rate 8.84 % 8.84 % Permanent differences 3.46 % 3.46 % Valuation allowance (46.30 )% (46.30 )% Effective rate 0.00 % 0.00 %

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 13 – COMMITMENTS AND CONTINGENCIES The Company previously leased property for its day-to-day operations and facilities for possible retail dispensary locations and cultivation locations as part of the process of applying for retail dispensary and cultivation licenses. Entry into Agreement to Acquire Real Property On June 17, 2016, EWSD entered into a Contract to Buy and Sell Real Estate (the “Acquisition Agreement”) with Tammy J. Sciumbato and Donnie J. Sciumbato (collectively, the “Sellers”) to purchase certain real property comprised of 116 acres of agricultural land, a barn and a farmhouse in Pueblo, Colorado (the “Property”). The closing of the Acquisition Agreement was scheduled to occur on or about September 22, 2016 (the “Closing”), with possession of the land and barn occurring 12 days after the Closing and possession of the farm house occurring on or before January 1, 2017. The Sellers were to rent back the farm house from the Company until January 1, 2017. The purchase price to acquire the Property is $650,000, including $10,000 paid by the Company as a deposit into the escrow for the Property. During the third quarter of 2016, the Acquisition Agreement was cancelled and the deposit was forfeited. Office Leases On August 1, 2011, the Company entered into a lease agreement for office space located in West Hollywood, California through June 30, 2017 at a current monthly rate of $14,828 per month. The Company moved to different offices in Los Angeles, CA in April 2015. The sublease on the office has a term of 18 months with monthly rent of $7,486. The landlord for the West Hollywood space has filed a suit against the Company and independent guarantors on the West Hollywood lease. The Company has expensed all lease payments due under the West Hollywood lease. The Company’s liability for the West Hollywood lease will be adjusted, if required, upon settlement of the suit with the landlord. On September 8, 2016, the court approved the landlord’s application for writ of attachment in the State of California in the amount of $374,402 against PVM. A trial date had been set for May 2017 (Note 11). On July 18, 2017, plaintiff filed a Request for Dismissal with Prejudice of the litigation in respect of PVM. Total rent expense under operating leases for the year ended December 31, 2017 and 2016 was $20,474 and $89,000, respectively. Consulting Agreements On December 7, 2015, the Company entered into a consulting agreement for marketing and PR services, for a term of six months, which was subsequently extended through August 30, 2016. Compensation under this agreement through May 30, 2016 was $25,000 per month, with twenty percent, or $5,000, of this amount to be paid in shares of Common Stock. Pursuant to the terms of the agreement, the number of shares issued is determined at the end of each quarter. Upon extension, the terms were adjusted to $15,000 per month for services, with $5,000 to be paid in shares of Common Stock. On November 30, 2017, the Court granted plaintiff’s request for a Default Judgment in the amount of $89,000. Further, the Court scheduled a hearing for December 14, 2017, in respect of expenses, attorney’s fees, and interest at a rate of 6.25%. On March 1, 2016, the Company entered into a consulting agreement for corporate financial advisory services, for a term of 12 months, which is cancellable anytime with 30 days written notice after the first 90 days. Compensation under this agreement consists of a retainer of $3,500 per month, plus 1,500,000 shares of Common Stock issuable in 375,000 share tranches on a quarterly basis. On September 9, 2016, this agreement was terminated and no more shares of Common Stock were issued. Litigation On May 22, 2013, we initiated litigation in the United States District Court in the District of Arizona against three shareholders of MedVend Holdings LLC (“MedVend”) in connection with a contemplated transaction that we entered into for the purchase of an approximate 50% ownership stake in MedVend for $4.1 million. The lawsuit alleged fraud and related claims arising out of the contemplated transaction during the quarter ended June 30, 2013. In January 2017, we settled the litigation and agreed to pay the original shareholders of MedVend an aggregate of $375,000 in 6 installments over three years. We defaulted on the original settlement agreement. MedVend unsuccessfully attempted to obtain a partial payment from us through certain court proceedings that it initiated regarding Dr. Bedrick’s component of the above-disclosed SEC Investigation and Wells Notice. On February 20, 2015, Michael A. Glinter, derivatively and on behalf of the Company, as a nominal defendant, and the Board and certain executive officers (Pejman Vincent Mehdizadeh, Matthew Feinstein, Bruce Bedrick, Thomas Iwanski, Guy Marsala, J. Mitchell Lowe, Ned Siegel, Jennifer Love, and C. Douglas Mitchell), filed a suit in the Superior Court of the State of California for the County of Los Angeles. The suit alleges breach of fiduciary duties and abuse of control by the defendants. Relief is sought awarding damages resulting from breach of fiduciary duty and to direct the Company and the defendants to take all necessary actions to reform and improve its corporate governance and internal procedures to comply with applicable law. The Company has entered into a Stipulation and Agreement of Settlement on October 16, 2015. See more detailed discussion below under Derivative Settlements On January 21, 2015, Josh Crystal on behalf of himself and of all others similarly situated filed a class action lawsuit in the U.S. District Court for Central District of California against the Company and certain past and present members of the Board (Pejman Vincent Mehdizadeh, Bruce Bedrick, Thomas Iwanski, Guy Marsala, and C. Douglas Mitchell). The suit alleges that the Company issued materially false and misleading statements regarding its financial results for the fiscal year ended December 31, 2013 and each of the interim financial periods that year. The plaintiff seeks relief of compensatory damages and reasonable costs and expenses or all damages sustained as a result of the wrongdoing. On April 23, 2015, the Court issued an Order consolidating the three related cases in this matter: Crystal v. Medbox, Inc. Gutierrez v. Medbox, Inc. Donnino v. Medbox, Inc. Class Settlement On January 18, 2015, Ervin Gutierrez filed a class action lawsuit in the U.S. District Court for the Central District of California. The suit alleges violations of federal securities laws through public announcements and filings that were materially false and misleading when made because they misrepresented and failed to disclose that the Company was recognizing revenue in a manner that violated US GAAP. The plaintiff seeks relief for compensatory damages and reasonable costs and expenses or all damages sustained as a result of the wrongdoing. On April 23, 2015, the Court issued an Order consolidating the three related cases in this matter: Crystal v. Medbox, Inc. Gutierrez v. Medbox, Inc. Donnino v. Medbox, Inc. Class Settlement On January 29, 2015, Matthew Donnino filed a class action lawsuit in the U.S. District Court for Central District of California. The suit alleges that the Company issued materially false and misleading statements regarding its financial results for the fiscal year ended December 31, 2013 and each of the interim financial periods that year. The plaintiff seeks relief for compensatory damages and reasonable costs and expenses or all damages sustained as a result of the wrongdoing. On April 23, 2015, the Court issued an Order consolidating the three related cases in this matter: Crystal v. Medbox, Inc. Gutierrez v. Medbox, Inc. Donnino v. Medbox, Inc. Class Settlement On February 12, 2015, Jennifer Scheffer, derivatively on behalf of the Company, Guy Marsala, Ned Siegel, Mitchell Lowe and C. Douglas Mitchell filed a lawsuit in the Eighth Judicial District Court of Nevada seeking damages for breaches of fiduciary duty regarding the issuance and dissemination of false and misleading statements and regarding allegedly improper and unfair related party transactions, unjust enrichment and waste of corporate assets. On April 17, 2015, Ned Siegel and Mitchell Lowe filed a Motion to Dismiss. On April 20, 2015, the Company filed a Joinder in the Motion to Dismiss. On July 27, 2015, the Court held a hearing on and granted the Motion to Dismiss without prejudice. The Company has entered into a Stipulation and Agreement of Settlement on October 16, 2015. See more detailed discussion below under Derivative Settlements On March 10, 2015, Robert J. Calabrese, derivatively and on behalf of the Company, as a nominal defendant, filed a suit in the United States District Court for the District of Nevada against certain Company officers and/or directors (Ned L. Siegel, Guy Marsala, J. Mitchell Lowe, Pejman Vincent Mehdizadeh, Bruce Bedrick, and Jennifer S. Love). The suit alleges breach of fiduciary duties and gross mismanagement by issuing materially false and misleading statements regarding the Company’s financial results for the fiscal year ended December 31, 2013 and each of the interim financial periods. Specifically, the suit alleges that defendants caused the Company to overstate the Company’s revenues by recognizing revenue on customer contracts before it had been earned. The plaintiff seeks relief for compensatory damages and reasonable costs and expenses for all damages sustained as a result of the alleged wrongdoing. The Company has entered into a Stipulation and Agreement of Settlement on October 16, 2015. See more detailed discussion below under Derivative Settlements On March 27, 2015, Tyler Gray, derivatively and on behalf of nominal defendant Medbox, Inc., filed a suit in the United States District Court for the District of Nevada against the Board and certain executive officers (Pejman Vincent Mehdizadeh, Matthew Feinstein, Bruce Bedrick, Thomas Iwanski, Guy Marsala, J. Mitchell Lowe, Ned Siegel, Jennifer S. Love, and C. Douglas Mitchell). The suit alleges breach of fiduciary duties and abuse of control. The plaintiff seeks relief for compensatory damages and reasonable costs and expenses for all damages sustained as a result of the alleged wrongdoing. Additionally, the plaintiff seeks declaratory judgments that plaintiff may maintain the action on behalf of the Company, that the plaintiff is an adequate representative of the Company, and that the defendants have breached and/or aided and abetted the breach of their fiduciary duties to the Company. Lastly the plaintiff seeks that the Company be directed to take all necessary actions to reform and improve its corporate governance and internal procedures to comply with applicable law. The Company has entered into a Stipulation and Agreement of Settlement on October 16, 2015. See more detailed discussion below under Derivative Settlements On May 20, 2015, Patricia des Groseilliers, derivatively and on behalf of the Company, as a nominal defendant, filed a suit in the United States District Court for the District of Nevada against the Board and certain executive officers (Pejman Vincent Mehdizadeh, Ned Siegel, Guy Marsala, J. Mitchell Lowe, Bruce Bedrick, Jennifer S. Love, Matthew Feinstein, C. Douglas Mitchell, and Thomas Iwanski). The suit alleges breach of fiduciary duties and unjust enrichment. The plaintiff seeks relief for compensatory damages and reasonable costs and expenses for all damages sustained as a result of the alleged wrongdoing. Additionally, the plaintiff seeks declaratory judgments that plaintiff may maintain the action on behalf of the Company, that the plaintiff is an adequate representative of the Company, and that the defendants have breached and/or aided and abetted the breach of their fiduciary duties to the Company. Lastly the plaintiff seeks that the Company be directed to take all necessary actions to reform and improve its corporate governance and internal procedures to comply with applicable law. The Company has entered into a Stipulation and Agreement of Settlement on October 16, 2015. See more detailed discussion below under Derivative Settlements On June 3, 2015, Mike Jones, derivatively and on behalf of the Company, as a nominal defendant., filed a suit in the U.S. District Court for Central District of California against the Board and certain executive officers (Guy Marsala, J. Mitchell Lowe, Ned Siegel, Jennifer S. Love, C. Douglas Mitchell, Pejman Vincent Mehdizadeh, Matthew Feinstein, Bruce Bedrick, and Thomas Iwanski). The suit alleges breach of fiduciary duties, abuse of control, and breach of duty of honest services. The plaintiff seeks relief for compensatory damages and reasonable costs and expenses for all damages sustained as a result of the alleged wrongdoing. Additionally the plaintiff seeks declaratory judgments that plaintiff may maintain the action on behalf of the Company, that the plaintiff is an adequate representative of the Company, and that the defendants have breached and/or aided and abetted the breach of their fiduciary duties to the Company. Lastly the plaintiff seeks that the Company be directed to take all necessary actions to reform and improve its corporate governance and internal procedures to comply with applicable law. On July 20, 2015, the Court issued an Order consolidating this litigation with those previously consolidated in the Central District (Crystal, Gutierrez, and Donnino). On October 7, 2015, the Court issued an Order modifying the July 20, 2015 Order consolidating the litigation so that the matters remain consolidated for the purposes of pretrial only. The Company has entered into a Stipulation and Agreement of Settlement on October 16, 2015. See more detailed discussion below under Derivative Settlement On July 20, 2015, Kimberly Freeman, derivatively and on behalf of nominal defendant Medbox, Inc., filed a suit in the Eighth Judicial District Court of Nevada against the Board and certain executive officers (Pejman Vincent Mehdizadeh, Guy Marsala, Ned Siegel, J. Mitchell Lowe, Jennifer S. Love, C. Douglas Mitchell, and Bruce Bedrick). The suit alleges breach of fiduciary duties and unjust enrichment. The plaintiff seeks relief for compensatory damages and reasonable costs and expenses for all damages sustained as a result of the alleged wrongdoing. Additionally, the plaintiff seeks declaratory judgments that plaintiff may maintain the action on behalf of the Company, that the plaintiff is an adequate representative of the Company, and that the defendants have breached and/or aided and abetted the breach of their fiduciary duties to the Company. Lastly, the plaintiff seeks that the Company be directed to take all necessary actions to reform and improve its corporate governance and internal procedures to comply with applicable law. The Company has entered into a Stipulation and Agreement of Settlement on October 16, 2015. See more detailed discussion below under Derivative Settlement On October 16, 2015, solely to avoid the costs, risks, and uncertainties inherent in litigation, the parties to the class actions and derivative lawsuits named above entered into settlements that collectively effect a global settlement of all claims asserted in the class actions and the derivative actions. The global settlement provides, among other things, for the release and dismissal of all asserted claims. The global settlement is contingent on final court approval, respectively, of the settlements of the class actions and derivative actions. If the global settlement does not receive final court approval, it could have a material adverse effect on the financial condition, results of operations and/or cash flows of the Company and its ability to raise funds in the future. On October 27, 2015, separate from the above lawsuits and settlement, Richard Merritts, derivatively and on behalf the Company, as a nominal defendant, filed a suit in the Superior Court of the State of California for the County of Los Angeles against the Board and certain executive officers (Guy Marsala, J. Mitchell Lowe, Ned Siegel, Jennifer S. Love, C. Douglas Mitchell, Pejman Vincent Mehdizadeh, Matthew Feinstein, Bruce Bedrick, Jeff Goh, and Thomas Iwanski). The suit titled Merritts v. Marsala, et al. Jones v. Marsala, et al Mike Jones v. Guy Marsala, et al. Derivative Settlements Class Settlement On December 1, 2015, Medbox and the class plaintiffs in Josh Crystal v. Medbox, Inc., et al. ● a cash payment to a settlement escrow account in the amount of $1,850,000, of which $150,000 will be paid by the Company and $1,700,000 will be paid by the Company’s insurers; ● a transfer of 2,300,000 shares of Common Stock to the settlement escrow account, of which 2,000,000 shares would be contributed by the Company and 300,000 shares of Common Stock by Bruce Bedrick; ● the net proceeds of the settlement escrow, after deduction of Court-approved administrative costs and any Court-approved attorneys’ fees and costs would be distributed to the Class; and ● releases of claims and dismissal of the action. By entering into the settlement, the settling parties have resolved the class claims to their mutual satisfaction. However, the final determination is subject to approval by the Federal Courts. Defendants have not admitted the validity of any claims or allegations and the settling plaintiffs have not admitted that any claims or allegations lack merit or foundation. If the global settlement does not receive final court approval, it could have a material adverse effect on the financial condition, results of operations and/or cash flows of the Company and its ability to raise funds in the future. Derivative Settlements As previously announced on October 22, 2015, on October 16, 2015, the Company, in its capacity as a nominal defendant, entered into a memorandum of understanding of settlement (the “Settlements”) in the following stockholder derivative actions: (1) Mike Jones v. Guy Marsala, et al. Jennifer Scheffer v. P. Vincent Mehdizadeh, et al. Kimberly Y. Freeman v. Pejman Vincent Mehdizadeh, et al. Tyler Gray v. Pejman Vincent Mehdizadeh, et al. Robert J. Calabrese v. Ned L. Siegel, et al. Patricia des Groseilliers v. Pejman Vincent Mehdizadeh, et al. Michael A. Glinter v. Pejman Vincent Mehdizadeh, et al. On December 3, 2015, the parties in the Jones v. Marsala By entering into the Settlements, the settling parties have resolved the derivative claims to their mutual satisfaction. The Individual Defendants have not admitted the validity of any claims or allegations and the settling plaintiffs have not admitted that any claims or allegations lack merit or foundation. Under the terms of the Settlements, the Company agrees to adopt and adhere to certain corporate governance processes in the future. In addition to these corporate governance measures, the Company’s insurers, on behalf of the Individual Defendants, will make a payment of $300,000 into the settlement escrow account and Messrs. Mehdizadeh and Bedrick will deliver 2,000,000 and 300,000 shares, respectively, of their shares of Common Stock into the Settlement escrow account. The funds and Common Stock in the Settlement escrow account will be paid as attorneys’ fees and expenses, or as service awards to plaintiffs. On September 16, 2016, solely to avoid the costs, risks, and uncertainties inherent in litigation, the parties entered into a Court-approved settlement regarding the Merritts Action. The settlement provides, among other things, for the release and dismissal of all asserted claims. Under the terms of the settlement, the Company agrees to adopt and to adhere to certain corporate governance processes in the future. In addition to these corporate governance measures, on or about October 3, 2016, the Company paid $135,000 to pay Merritts’ counsel for attorneys’ fees and expenses, or as service awards to Merritts that are approved and awarded by the Court. SEC Investigation In October 2014, the Board appointed a special committee (the “Special Committee”) to investigate issues arising from a federal grand jury subpoena pertaining to the Company’s financial reporting which was served upon the Company’s predecessor independent registered public accounting firm as well as certain alleged wrongdoing raised by a former employee of the Company. The Company was subsequently served with two SEC subpoenas in early November 2014. The Company is fully cooperating with the grand jury and SEC investigations. In connection with its investigation of these matters, the Special Committee in conjunction with the Audit Committee initiated an internal review by management and by an outside professional advisor of certain prior period financial reporting of the Company. The outside professional advisor reviewed the Company’s revenue recognition methodology for certain contracts for the third and fourth quarters of 2013. As a result of certain errors discovered in connection with the review by management and its professional advisor, the Audit Committee, upon management’s recommendation, concluded on December 24, 2014 that the Consolidated Financial Statements for the year ended December 31, 2013 and for the third and fourth quarters therein, as well as for the quarters ended March 31, 2014, June 30, 2014 and September 30, 2014, should no longer be relied upon and would be restated to correct the errors. On March 6, 2015 the audit committee determined that the Consolidated Financial Statements for the year ended December 31, 2012, together with all three-, six-, and nine-month financial information contained therein, and the quarterly information for the first two quarters of the 2013 fiscal year should also be restated. On March 11, 2015, the Company filed its restated Form 10 Registration Statement with the SEC with restated financial information for the years ended December 31, 2012 and December 31, 2013, and on March 16, 2015, the Company filed amended and restated quarterly reports on Form 10-Q, with restated financial information for the periods ended March 31, June 30 and September 30, 2014, respectively. In March 2016, the staff of the Los Angeles Regional Office of the U.S. Securities and Exchange Commission advised counsel for the Company in a telephone conversation, followed by a written “Wells” notice, that it is has made a preliminary determination to recommend that the Commission file an enforcement action against the Company in connection with misstatements by prior management in the Company’s financial statements for 2012, 2013 and the first three quarters of 2014. A Wells Notice is neither a formal allegation of wrongdoing nor a finding that any violations of law have occurred. Rather, it provides the Company with an opportunity to respond to issues raised by the Staff and offer its perspective prior to any SEC decision to institute proceedings. In March 2017, the SEC and the Company settled this matter. The Company consented to the entry of a final judgment permanently enjoining it from violations of Sections 5(a), 5(c), and 17(a) of the Securities Act and Sections 10(b), 13(a), 13(b)(2)(A), and 13(b)(2)(B) of the Exchange Act and Rules 10b-5, 12b-20, 13a-11, and 13a-13 thereunder. In connection with the settlement, the Company did not have any monetary sanctions or penalties assessed against it. Other litigation Whole Hemp complaint A complaint was filed by Whole Hemp Company, LLC d/b/a Folium Biosciences (“Whole Hemp”) on June 1, 2016, naming Notis Global, Inc. and EWSD (collectively, “Notis”), as defendants in Pueblo County, CO district court. The complaint alleges five causes of action against Notis: misappropriation of trade secrets, civil theft, intentional interference with prospective business advantage, civil conspiracy, and breach of contract. All claims concern contracts between Whole Hemp and Notis for the Farming Agreement and the Distributor Agreement. The court entered an ex parte On August 12, 2016, the court ordered that all of Whole Hemp’s plants in Notis’ possession be destroyed, which occurred by August 24, 2016, at which time the temporary restraining order was dissolved and the parties will soon file a motion to dismiss the district court action. On June 29, 2017, the parties jointly stipulated to the dismissal of all claims and counterclaims with prejudice. Notis commenced arbitration in Denver, CO on August 2, 2016, seeking injunctive relief and alleging breaches of the contracts between the parties. Whole Hemp filed its Answer and counterclaims on September 6, 2016, asserting similar allegations that were asserted to the court. On September 30, 2016, the arbitrator held an initial status conference and agreed to allow EWSD and Notis to file a motion to dismiss some or all of Whole Hemp’s claims by no later than October 28, 2016. The parties were also ordered to make initial disclosures of relevant documents and persons with knowledge of relevant information by October 21, 2016. In light of the court order to destroy all Whole Hemp plants, the Company has immediately expensed all Capitalized agricultural costs of $73,345 related to Whole Hemp plants. As of December 31, 2016, the Company capitalized $160,131 that related to Whole Hemp plants. As noted above, the Company’s long-term strategy is to maintain tight control of its supply chain. The continuing default by Whole Hemp was conductive to the Company’s efforts to eliminate outside vendors in the supply chain and control production from “Seed to Sale.” The Company’s decision to terminate the Whole Hemp Agreements comports with its long-term strategy to maintain tight control of its supply chain. West Hollywood Lease The lease for the former office at 8439 West Sunset Blvd. in West Hollywood, CA has been partially subleased. The Company plans to sublease the remainder of the office in West Hollywood, CA and continues to incur rent expense while the space is being marketed. The landlord for the prior lease filed a suit in Los Angeles Superior Court in April 2015 against the Company for damages they allege have been incurred from unpaid rent and otherwise. In January 2016, the landlord filed a first amended complaint adding the independent guarantors under the lease as co-defendants and specifying damages claim of approximately $300,000. On September 8, 2016, the court approved Mani Brothers’ application for writ of attachment in the State of California in the amount of $374,402 against PVM. A trial date was set in May 2017. On March 16, 2017, the Company and Mani Brothers agree to settle the amount owed if the Company paid $40,000 before July 2017. The Company paid the $40,000 in four monthly payments commencing in April 2017. On July 24, 2017, the case was dismissed against the Company. Los Angeles Lease The Company’s former landlord, Bank Leumi, filed an action against the Company in Los Angeles Superior Court for breach of lease on August 31, 2016, seeking $29,977 plus fees and interest, in addition to rent payment for September 2016. The Company filed a response to the complaint on September 21, 2016, and a case management conference is scheduled for December 9, 2016. In November 2016, the parties entered into a Settlement Agreement and General Release, pursuant to which the Company agreed to an eight-payment plan in favor of the Bank, commencing December 2016 and terminating July 2017. All of the payments, which aggregated $46,522 for rent, fees, and costs, have been made. Creaxion On August 23, 2017, Creaxion Corporation filed a Complaint in the Superior Court of Fulton County, Georgia, styled Creaxion Corporation, Plaintiff, v. Notis Global, Inc., Defendant Sheppard, Mullin On October 27, 2017, Sheppard Mullin filed a Complaint in the Superior Court of the State of California for the County of Los Angeles, styled Sheppard, Mullin, Richter & Hampton LLP, a California limited liability partnership, plaintiff v. Notis Global, Inc., a Nevada corporation, formerly known as Medbox, Inc.; and Does 1-10, inclusive, Defendants Pueblo Farm – Management Services Agreement On May 31, 2017, the Company, and two of its subsidiaries, EWSD and Pueblo Agriculture Supply and Equipment LLC, and Trava LLC, a Florida limited liability company that has lent various sums to the Company (“Trava”; referenced above as the “PCH Lender”), entered into a Management Services Agreement (the “MS Agreement”) in respect of the Company’s hemp grow-and-extraction operations located in Pueblo, Colorado (the “Pueblo Farm”). The MS Agreement has a 36-month term with two consecutive 12-month unilateral options exercisable in the sole discretion of Trava. Pursuant to the provisions of the MS Agreement, Trava shall collect all revenue generated by the Pueblo Farm operations. Further, Trava is to satisfy all of the Pueblo Farm-related past due expenses and, subject to certain limitations, to pay all current and future operational expenses of the Pueblo Farm operations. Finally, commencing October 2017, Trava is obligated to make the monthly mortgage payments on the Pueblo Farm, although the Company remains responsible for any and all “balloon payments” due under the mortgage. On a cumulative calendar monthly cash-on-cash basis, Trava is obligated to tender to the Company or, at the Company’s option, to either or both of those subsidiaries, an amount equivalent to 51% of the net cash for each such calendar month. Such monthly payments are on the 10 th On January 29, 2018, the parties to the MS Agreement entered into a subsequent agreement (the “Termination Agreement”), pursuant to which they agreed to terminate the MS Agreement in full. By its terms, the Termination Agreement did not modify any of the then-extant agreements among the parties. In connection with the termination of the MS Agreement and in lieu of any compensation and reimbursement that otherwise was to have been tendered by Trava, the parties agreed that, on or before March 31, 2019, the Company would tender to Trava the sum of not less than $250,000.00, subject to increase depending upon the results of the Farm’s 2018 harvest season. Pursuant to the terms of the Termination Agreement, on March 31, 2019, the Company tendered the sum of approximately $265,000 to Trava. Commencing in September 2017 in connection with Trava’s monthly lending to the Company funds sufficient for the Pueblo Farm’s monthly operational expenses of the Pueblo Farm operations, the Company amended the MS Agreement to provide that, from time to time, Trava may exercise its rights to convert some or all of the notes that evidence its lending of funds into shares of Common Stock at a fixed conversion price of $.0001 pre-share. If Trava converts, in whole or in part, any one or more of such notes, then (unless (i) thereafter, the Company is unable to accommodate any future such conversions because of a lack of authorized, but unissued or unreserved, shares or (ii) the public market price for a share of Common Stock becomes “no bid”), Trava shall continue to exercise its conversion rights in respect of all of such notes (to the 4.9% limitations set forth therein) and shall diligently sell the shares of Common Stock into which any or all of such notes may be converted (collectively, the “Underlying Shares”) in open market or other transactions (subject to any limitations imposed by the Federal securities laws and set forth in any “leak-out” type of arrangements in respect of the “underlying shares” to which Trava is a party). Trava acknowledged that any proceeds derived by it from such sales of the underlying shares shall, on a dollar-for-dollar basis, reduce the Company’s financial obligations under the notes. Once Trava has received sufficient proceeds from such sales to reduce the aggregate obligations thereunder to nil (which reductions shall include any and all funds that Trava may have otherwise received in connection with the respective rights and obligations of the parties to the MSA), then the MSA shall be deemed to have been cancelled without any further economic obligations between Trava and the Company and Trava’s purchase right shall, accordingly, be extinguished. Jeffery Goh We are a party to certain litigation that was filed by Jeff Goh, one of our former directors and executive officers in Superior Court for the state of California, County of Orange, styled JEFF GOH, an individual, Plaintiff, vs. MEDBOX HOLDINGS, INC., a Nevada corporation; NOTIS GLOBAL, INC., a Nevada corporation; and DOES 1 through 100, inclusive,

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	NOTE 14 – SUBSEQUENT EVENTS The Company evaluates events that have occurred after the balance sheet date of December 31, 2017, through the date which the Consolidated Financial Statements were issued. Based upon the review, other than described in Note 14 – Subsequent Events, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the Consolidated Financial Statements. Subsequent to December 31, 2017, the Company issued 20 convertible notes to third party lenders totaling $2,143,499. These notes accrue interest at a rate of 10% per annum and mature with interest and principal both due between December 2018 through September 2020. Subsequent to December 31, 2017, the Company issued 2 notes to third party lenders totaling $200,000. These notes accrue interest at a rate of 10% per annum and mature with interest and principal both due between April 2019 through May 2019. Subsequent to December 31, 2017, the Company settled Investor #2 notes with a principal balance of $2,595,895 for $2,350,000. The Company is currently in default on the settlement agreement. Southwest Farms Note Modification On June 20, 2018, Shi Farms entered into a loan modification agreement (the “Agreement”) to extend the term of the EWSD Secured Note. Pursuant to the Agreement, the maturity date of the EWSD Secured Note is extended to August 1, 2020, and Shi Farms will continue to make payments in the same manner as previously required through and including July 1, 2020, with the final balloon payment due and payable on August 1, 2020. Additionally, on May 31, 2019, Shi Farms paid Southwest Farms an additional required principal payment of $250,000, which does not reduce any regularly scheduled payments, but will reduce the final balloon payment. Office Lease On January 25, 2019, the Company entered into a seven-year operating lease for approximately 1,840 square feet of office space for employees in Red Bank, New Jersey. The commencement date of this agreement was May 1, 2019; currently, the Company is operating out of a temporary space while the full space is prepared. The monthly rent is $1,200 for the temporary space which ends August 30, 2019. The minimum monthly lease payments, once the space is complete, will be $3,000. Canbiola Joint Venture On July 11, 2019, NY – SHI, LLC, a New York limited liability company (“NY – SHI”), and Shi Farms (collectively, the “Company Subs”) entered into a joint venture agreement (the “Joint Venture Agreement”) with Canbiola Inc., a Florida corporation (“Canbiola”), and NY Hemp Depot, LLC, a Nevada limited liability company (“Canbiola Sub”). The purpose of the joint venture is to develop and implement a business model referred to as the “Depot Model” to aggregate and purchase fully-grown, harvested industrial hemp from third-party farmers in the State of New York to be processed in any processing facility chosen by NY – SHI (the “Joint Venture”). Pursuant to the Joint Venture Agreement, the Company Subs will jointly seek farmers to grow and cultivate industrial hemp in the State of New York for the Joint Venture. In addition, the Joint Venture may sell to the farmers feminized hemp seeds, clone plants, and additional materials required to grow and cultivate industrial hemp and provide to the farmers the initial training reasonably required for them to grow industrial hemp. Canbiola Sub is responsible for securing the building on behalf of the Joint Venture in the State of New York to house certain of the operations of the business of the Joint Venture (the “NY Hemp Depot Facility”). Canbiola Sub will manage and direct the day-to-day operations of the Joint Venture and provide farmer recruitment services. NY – SHI is responsible for providing to the Joint Venture technical expertise regarding the growth and cultivation of industrial hemp, a license from the New York State Department of Agriculture and Markets that permits the growth of industrial hemp (the “Cultivating License”), and the farmer recruitment services. Upon the execution of the Joint Venture Agreement, Canbiola Sub delivered to NY – SHI a cash payment of $500,000 and, on July 22, 2019, Canbiola issued and delivered $500,000 in value of Canbiola’s common stock (12,074,089 shares) to NY– SHI, upon NY – SHI’s amendment of the Cultivating License to add the NY Hemp Depot Facility. Additionally, SHI Farms has agreed to sell certain isolate to Canbiola or its designated affiliate at the cost of processing the isolate from biomass and granted Canbiola Sub an interest in the one and one-half percent payments due to SHI Farms in connection with its agreements with Mile High Labs. The “gross profits” from the Joint Venture, which are defined as gross revenues less certain direct operational costs, will be distributed quarterly in arrears with the first distribution scheduled to be made on March 31, 2020, of which 70% is to be distributed to Canbiola Sub and 30% is to be distributed to NY – SHI. Aeon Investment and Royalty Agreement On March 12, 2018, Shi Farms entered into an investment and royalty agreement (the “March 2018 Aeon Agreement”) with Aeon Funds, LLC (“Aeon”), whereby Aeon committed to use its best efforts to invest $1 million in Shi Farms. These funds will be used for growing and harvesting 100 acres of industrial hemp at the Farm from March 1, 2018 through November 30, 2019 (the “2018-2019 Crop”), and thereafter, for processing and marketing Shi Farms’ products. Pursuant to the terms of the March 2018 Aeon Agreement, Shi Farms will pay royalties to Aeon in an amount equal to 50% of gross sales of product from the 2018-2019 Crop until the principal investment is fully repaid. Shi Farms will then pay 20% of gross sales of the 2018-2019 Crop to Aeon until gross sales equal $10 million. Once gross sales exceed $10 million, Shi Farms will pay Aeon 10% of gross sales. Payments will be made monthly until all products from the 2018-2019 harvest are sold. The March 2018 Aeon Agreement provides that the Company will also issue to Aeon shares of Common Stock valued at $100,000 and grants Aeon a five-year right of first negotiation, in the event Shi Farms seeks additional financing. In July of 2019, at the request of Aeon, the share issuance was amended to become an issuance of warrants for the purchase of $100,000 of shares of our common stock. As of July 31, 2019, in connection with the March 2018 Aeon Agreement, Shi Farms had received an investment of $1,000,000 from Aeon and has repaid $1,374,892.91 of that investment. AAG Harvest 2019 Revenue Sharing Agreement On May 1, 2019, Shi Farms entered into a revenue sharing agreement (the “RS Agreement”) with AAG Harvest 2019, LLC, a Delaware limited liability company (“AAG Harvest”), whereby AAG Harvest agreed to invest a portion of the proceeds from its offering of limited liability company interests in Shi Farms. The RS Agreement provides that AAG Harvest will use its best efforts to provide up to $3,910,000 of funding (the “Funding”) to Shi Farms, and allows funding to increase to $7,100,000 by mutual agreement of Shi Farms and AAG Harvest. Shi Farms will use the funding to grow and harvest approximately 1,200 acres of industrial hemp at the Farm in Pueblo, Colorado, its co-op location in Oklahoma, and its co-op location in Southern Colorado from approximately May 2019 through November 2019 (the “2019 Crop”). In exchange for the investment, AAG Harvest will receive payments equal to 25% of Shi Farms’ gross sales of the 2019 Crop until AAG Harvest has received an amount equivalent to the amount of capital raised by AAG Harvest to fund the Funding (approximately 118% of the Funding). After AAG Harvest has received this amount, Shi Farms will pay 12.5% of gross sales of the 2019 Crop to AAG Harvest. Payments to AAG Harvest are due within 45 days of each calendar quarter until the 2019 Crop is entirely sold. As of August 22, 2019, in connection with the RS Agreement, Shi Farms has received funding of $2,854,775 from AAG Harvest. Preferred Units Placement Agreement On November 19, 2018, Shi Farms entered into an agreement with AEON Capital, Inc. (“Aeon Capital”), whereby Aeon Capital provided placement agent services with respect to certain preferred membership units of the Company. In consideration for the services provided, Shi Farms has agreed to pay Aeon Capital a cash fee of up to 10% of the gross proceeds from the sale of units to investors introduced by Aeon Capital, and 2.5% of the gross proceeds from the sale of units to investors introduced by the Company. In connection with this agreement, Aeon Capital has placed $3,915,000 in preferred membership units, for which Shi Farms has paid fees of 193,490 . January 2018 Notis Global / Shi Farms Amendment to Joint Venture Agreement On January 29, 2018, the Company (with Shi Farms as an interested party) entered into an agreement that amended the Company’s prior joint venture agreement with an individual consultant (the “Individual Consultant”), whereby the Individual Consultant was to provide certain consulting services necessary to farm, prepare, and plant 98 acres at the Pueblo, Colorado farm for the 2018 harvest. In connection with the 2017 harvest, the Company agreed to pay the Individual Consultant $75,000 in cash and $25,000 in “clone credits.” Total base compensation under the amended agreement was from $100,000 (1 to 50 acres) to $200,000 (151- 200 acres), depending on the number of acres actually planted, with additional compensation for additional planted acres, and, in each case, with the opportunity of a bonus in an amount equivalent to the relevant base compensation. The parties agreed that the compensation would be paid on a monthly basis, which will vary based upon the season. The term of the agreement commenced, when executed on January 29, 2018, and is to continue through November 4, 2020 (the expiration date of the original, pre-amended joint venture agreement). This is a summary of the amendment to the joint venture agreement and does not include every material term. Please review the entire amendment, a complete copy of which is filed as an exhibit to this Annual Report. March 2019 Shi Farms Biomass Joint Venture Agreement On March 29, 2019, Shi Farms entered into a joint venture agreement with two individuals (one of whom was the subject of the January 2018 joint venture agreement disclosed above) and their limited liability company (the “Consultants”), whereby the Consultants were (i) to provide their advice and assistance to Shi Farms in the cultivation of hemp and (ii) to plant 450 acres on property leased from the Consultants’ company. Shi Farms agreed to provide them with the required seeds (approximately 3,500 per acre) and to pay for their cultivation costs at the rate of $4,200 per acre for a total of $1,890,000 (or up to $150,000 per month – some months are expected to be less based on the growing season). The parties agreed that the Consultants would deliver the cultivated biomass to Shi Farms, which agreed to use its best efforts to monetize the delivered biomass to an intended and final product ( i e Mile High Labs – Partner Farm and Supply Agreements Partner Farm Agreement On May 10, 2019, Shi Farms entered into a partner farm agreement (the “Partner Farm Agreement”) with Mile High Labs, Inc., a Colorado corporation (“Mile High”), whereby Shi Farms has agreed to produce, sell and/or deliver certain dried hemp products (the “Product”) to Mile High, and Mile High has agreed to purchase such Product from Shi Farms and/or provide certain processing services (the “Processing Services”). Among other obligations, Shi Farms has agreed to provide a physical location to perform such Processing Services on the Farm, the infrastructure necessary to access the Farm and the construction of certain structures for the purpose of conducting the Processing Services on the Farm. Among other obligations, Mile High is required to provide, transport and install all necessary equipment to operate the processing facilities located on the Farm, subject to the terms and provisions therein. Mile High has also agreed to provide Shi Farms with priority processing services for the Product specified in the Partner Farm Agreement, of up to 25% of the production capacity of the processing facilities operated by Mile High on the Farm. The Partner Farm Agreement will have an initial term of five years and shall renew automatically thereafter for one-year increments and is terminable by either Mile High or Shi Farms upon 60 days’ written notice. Shi Farms will receive 20% of all sales of the Product and Mile High will receive 80% of the sales price, subject to the payment schedule and terms attached thereto. Supply Agreement In connection with, and pursuant to, the Partner Farm Agreement, Shi Farms also entered into a supply agreement (the “Supply Agreement”), on May 10, 2019, with Mile High, whereby Shi Farms will produce and sell to Mile High, and Mile High will purchase and accept from Shi Farms, the Products enumerated in the Partner Farm Agreement and the Supply Agreement in quantities specified in the two agreements and by Mile High. Pursuant to the Supply Agreement, Mile High and Shi Farms have agreed, among other things, to sell the Product as partners and to co-brand the finished Product. Should Mile High establish a cooperative advertising and promotional program, Shi Farms will be required to pay additional fees. The initial term of the Supply Agreement is five years and shall renew automatically thereafter for one-year increments and is terminable by either Mile High or Shi Farms upon 60 days’ written notice.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Going Concern	Going Concern The Consolidated Financial Statements were prepared on a going concern basis. The going concern basis assumes that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business. During the year ended December 31, 2017, the Company had a net loss from operations of approximately $117.3 million, negative cash flow from operations of $1.58 million and negative working capital of $158.7 million. During the year ended December 31, 2016, the Company had a net loss of approximately $17.7 million, negative cash flow from operations of $3.6 million and negative working capital of $37.7 million. The Company will need to raise capital in order to fund its operations. As of the date of this filing, the Company is in default on all notes outstanding. The Company is unable to predict the outcome of these matters; however, legal action taken by the Company’s lenders could have a material adverse effect on the financial condition, results of operations and/or cash flows of the Company and its ability to raise funds in the future. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the issuance of these financial statements. The ability to continue as a going concern is dependent on the Company’s ability to raise additional capital and implement its business plan. The Consolidated Financial Statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Management’s plans include: The Company expects that EWSD, which owns the 320 acre Farm in Pueblo, Colorado, will generate recurring revenues for the Company through farming hemp, extracting and selling CBD oil, and collecting fees from production related to extracting CBD oil for other farmers, while controlling the full production cycle to ensure consistent quality. Lastly, management is actively seeking additional financing over the next few months to fund operations. The Company will continue to execute on its business model by attempting to raise additional capital through the sales of debt or equity securities or other means. However, there is no guarantee that such financing will be available on terms acceptable to the Company, or at all. It is uncertain whether the Company can obtain financing to fund operating deficits until profitability is achieved. This need may be adversely impacted by: unavailability of financing, uncertain market conditions, the success of the crop growing season, the demand for CBD oil, the ability of the Company to obtain financing for the equipment and labor needed to cultivate hemp and extract the CBD oil, and adverse operating results. The outcome of these matters cannot be predicted at this time. On May 24, 2016, the Company received a notice from the OTC Markets Group Inc. (“OTC Markets”) that the Company’s bid price was below $0.01 and that the Company did not meet the Standards for Continued Eligibility for OTCQB pursuant to OTC Markets’ Standards. If the bid price did not close at or above $0.01 for ten consecutive trading days by November 20, 2016, the Company would be moved to the OTC Pink ® ® ® ®
Principles of Consolidation	Principles of Consolidation The Consolidated Financial Statements include the accounts of Notis Global, Inc. and its wholly-owned subsidiaries, as named in Note 1 above. All intercompany transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Critical accounting estimates are estimates for which (a) the nature of the estimate is material due to the levels of subjectivity and judgment necessary to account for highly uncertain matters or the susceptibility of such matters to change and (b) the impact of the estimate on financial condition or operating performance is material. The Company’s critical accounting estimates and assumptions affecting the financial statements were: (i) Assumption as a going concern (ii) Fair value of long-lived assets: (iii) Valuation allowance for deferred tax assets (iv) Estimates and assumptions used in valuation of equity instruments These significant accounting estimates or assumptions bear the risk of change due to the fact that there are uncertainties attached to these estimates or assumptions, and certain estimates or assumptions are difficult to measure or value. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates.
Discontinued Operations	Discontinued Operations US GAAP requires the results of operations of a component of an equity that either has been disposed of or is classified as held for sale to be reported as discontinued operations in the consolidated financial statements if the sale or disposition represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results .
Concentrations of Credit Risk	Concentrations of Credit Risk The Company maintains cash balances at several financial institutions that are insured by the Federal Deposit Insurance Corporation up to $250,000. The Company has not experienced any losses in such accounts and periodically evaluates the credit worthiness of the financial institutions and has determined the credit exposure to be negligible.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Pursuant to ASC No. 825, Financial Instruments Embedded derivative – The Company’s convertible notes payable include embedded features that require bifurcation due to a reset provision and are accounted for as a separate embedded derivative (see Note 7). The Company estimated the fair value of the conversion feature derivatives embedded in the convertible debentures based on a Monte Carlo Simulation model (“MCS”). The MCS model was used to simulate the stock price of the Company from the valuation date through to the maturity date of the related debenture and to better estimate the fair value of the derivative liability due to the complex nature of the convertible debentures and embedded instruments. Management believes that the use of the MCS model compared to the Black-Scholes-Merton model as previously used would provide a better estimate of the fair value of these instruments The Company valued these embedded derivatives using a “with-and-without method,” where the value of the Convertible Debentures including the embedded derivatives, is defined as the “with”, and the value of the Convertible Debentures excluding the embedded derivatives, is defined as the “without.” This method estimates the value of the embedded derivatives by observing the difference between the value of the Convertible Debentures with the embedded derivatives and the value of the Convertible Debentures without the embedded derivatives. The Company believes the “with-and-without method” results in a measurement that is more representative of the fair value of the embedded derivatives. For each simulation path, the Company used the Geometric Brownian Motion (“GBM”) model to determine future stock prices at the maturity date. The inputs utilized in the application of the GBM model included a starting stock price, an expected term of each debenture remaining from the valuation date to maturity, an estimated volatility, and a risk-free rate. For the years ended December 31, 2017 and 2016, the Company estimated the fair value of the conversion feature derivatives embedded in the convertible debentures based on an internally calculated adjustment to the MCS valuation determined at December 31, 2016. This adjustment took into consideration the changes in the assumptions, such as market value and expected volatility of the Common Stock, and the discount rate used in the December 31, 2016, valuation as compared to December 31, 2017.
Warrants	Warrants The Company reexamined the determination made as of December 31, 2016, that it did not have sufficient authorized shares available for all of their outstanding warrants to be classified in equity at December 31, 2017, and concluded there still were insufficient authorized shares (Note 7). Therefore, the Company recognized a warrant liability as of December 31, 2017. The Company estimated the fair value of the warrant liability based on the Black-Scholes-Merton model. The key assumptions used consist of the price of the Company’s stock, a risk-free interest rate based on the average yield of a one- to three-year Treasury note (based on remaining term of the related warrants), and expected volatility of the Common Stock over the remaining life of the warrants. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly. Level 3 Significant unobservable inputs that cannot be corroborated by market data. The assets or liabilities’ fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of the relevant assets and liabilities that are measured at fair value on a recurring basis: December 31, 2017 Total Quoted Prices Quoted Prices for Similar Assets or Liabilities in Active Significant Unobservable Inputs Warrant liability 3,528,602 - - 3,528,602 Option liability 299,965 - - 299,965 Derivative liability 113,636,474 - - 113,636,474 Total liabilities $ 117,465,041 $ - $ - $ 117,465,041 December 31, 2016 Total Quoted Prices Quoted Prices Significant Unobservable Inputs Warrant liability 14,430 - - 14,430 Derivative liability 15,635,947 - - 15,635,947 Total liabilities $ 15,650,377 $ - $ - $ 15,650,377 The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis: For the year ended December 31, 2017 Total January 1, 2017 15,650,377 Initial recognition of conversion feature 7,781,259 Initial recognition of warrant liability 3,277,052 Initial recognition of option liability 299,925 Change in fair value of conversion feature 90,219,268 Change in fair value of warrant liability 237,120 Change in fair value of option liability 40 Ending Balance, December 31, 2017 $ 117,465,041 For the year ended December 31, 2016 Total January 1, 2016 $ 20,186,594 Initial recognition of conversion feature 581,817 Change in fair value of conversion feature 33,271,611 Gain on extinguishment of debt (37,464,075 ) Change in fair value of liability (918,969 ) Unrealized loss on marketable securities (6,601 ) December 31, 2016 15,650,377
Revenue Recognition	Revenue Recognition Revenues from Cannabidiol oil product The Company recognizes revenue from the sale of Cannabidiol oil products (“CBD oil”) upon shipment, when title passes, and when collectability is reasonably assured. Cost of Revenue Cost of revenue consists primarily of expenses associated with the delivery and distribution of the Company’s products and services. Under the Company’s prior business model, the Company only began capitalizing costs when it obtained a license and a site for operation of a customer dispensary or cultivation center. The previously capitalized costs are charged to cost of revenue in the same period that the associated revenue is earned. In the case where it is determined that previously inventoried costs are in excess of the projected net realizable value of the sale of the licenses, then the excess cost above net realizable value is written off to cost of revenues. Cost of revenues also includes the rent expense on master leases held in the Company’s name, which are subleased to the Company’s operators. In addition, cost of revenue related to the Company’s vaporizer line of products consists of direct procurement cost of the products along with costs associated with order fulfillment, shipping, inventory storage and inventory management costs.
Cash and cash equivalents	Cash and cash equivalents The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of December 31, 2017 and 2016, the Company held no cash equivalents. The Company’s policy is to place its cash with high credit quality financial instruments and institutions and limit the amounts invested with any one financial institution or in any type of instrument. Deposits held with banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash.
Accounts Receivable and Allowances	Accounts Receivable and Allowances Accounts receivable are recorded at the invoiced amount and are not interest bearing. The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. The Company makes ongoing assumptions relating to the collectability of its accounts receivable in its calculation of the allowance for doubtful accounts. In determining the amount of the allowance, the Company makes judgments about the creditworthiness of customers based on ongoing credit evaluations and assesses current economic trends affecting its customers that might impact the level of credit losses in the future and result in different rates of bad debts than previously seen. The Company also considers its historical level of credit losses. As of December 31, 2017 and 2016, there was an allowance for doubtful accounts of $0.
Inventory	Inventory The Company utilizes lower of standard cost or net realizable value method. During the years ended December 31, 2017 and 2016, the Company recorded an impairment of $0 and $32,300 respectively, that was recorded to cost of revenues.
Capitalized Agricultural Costs	Capitalized agricultural costs Capitalized agricultural costs consists of pre-harvest agricultural costs, including irrigation, fertilization, seeding, laboring, other ongoing crop and land maintenance activities and work-in-progress activities. All capitalized agricultural costs are accumulated and capitalized as incurred. The Company has reflected the capitalized agriculture costs as a current asset as the growing cycle of the crops are estimated to be six months to a year.
Basic and Diluted Net Income/Loss Per Share	Basic and Diluted Net Income/Loss Per Share Basic net loss per share of Common Stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of Common Stock outstanding during the period. Diluted net loss per share of Common Stock is determined using the weighted-average number of shares of Common Stock outstanding during the period, adjusted for the dilutive effect of Common Stock equivalents. In periods when losses are reported, which is the case for the years ended December 31, 2017 and 2016 presented in these Consolidated Financial Statements, the weighted-average number of shares of Common Stock outstanding excludes Common Stock equivalents because their inclusion would be anti-dilutive. The Company had the following Common Stock equivalents at December 31, 2017 and 2016: December 31, 2017 December 31, 2016 Warrants 11,765,757,748 69,757,748 Options 1,000,000,000 - Convertible notes – related party 10,500,000 10,500,000 Convertible notes 465,782,195,939 114,808,810,010 Totals 478,558,453,687 114,889,067,758
Property and Equipment	Property and Equipment Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The Company uses accelerated depreciation methods for tax purposes where appropriate. The estimated useful lives for significant property and equipment categories are as follows: Vehicles 5 years Furniture and Fixtures 3 - 5 years Office equipment 3 years Machinery 2 years Buildings 10 - 39 years
Income Taxes	Income Taxes The Company accounts for income taxes under the asset and liability method. The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the Consolidated Financial Statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The components of the deferred tax assets and liabilities are classified as current and non-current based on their characteristics. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. In addition, the Company’s management performs an evaluation of all uncertain income tax positions taken or expected to be taken in the course of preparing the Company’s income tax returns to determine whether the income tax positions meet a “more likely than not” standard of being sustained under examination by the applicable taxing authorities. This evaluation is required to be performed for all open tax years, as defined by the various statutes of limitations, for federal and state purposes.
Commitments and Contingencies	Commitments and Contingencies Certain conditions may exist as of the date the Consolidated Financial Statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management and its legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Consolidated Financial Statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed. The Company accrues all legal costs expected to be incurred per event. For legal matters covered by insurance, the Company accrues all legal costs expected to be incurred per event up to the amount of the deductible.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers,” which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for annual reporting periods for public business entities beginning after December 15, 2017, including interim periods within that reporting period. The new standard permits the use of either the retrospective or cumulative effect transition method. The Company is currently evaluating the effect that ASU 2014-09 will have on its financial statements and related disclosures. The Company has not yet selected a transition method nor determined the effect of the standard on its ongoing financial reporting. On July 22, 2015, the FASB issued a new standard that requires entities to measure most inventory “at the lower of cost and net realizable value,” thereby simplifying the current guidance under which an entity must measure inventory at the lower of cost or market. The new standard will not apply to inventories that are measured by using either the last-in, first-out (LIFO) method or the retail inventory method. The new standard will be effective for fiscal years beginning after December 15, 2016, and interim periods in fiscal years beginning after December 15, 2016. The adoption did not have a material effect on its financial position or results of operations or cash flows. In April 2015, the FASB issued a new standard that requires an entity to determine whether a cloud computing arrangement contains a software license. If the arrangement contains a software license, the entity would account for the fees related to the software license element in a manner consistent with how the acquisition of other software licenses is accounted for. If the arrangement does not contain a software license, the customer would account for the arrangement as a service contract. The new standard will be effective for fiscal years beginning after December 15, 2015, and interim periods in fiscal years beginning after December 15, 2016. The adoption did not have a material effect on its financial position or results of operations or cash flows. In February 2016, the FASB issued “Leases (Topic 842)” (ASU 2016-02). This update amends leasing accounting requirements. The most significant change will result in the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under current guidance. The new guidance will also require significant additional disclosures about the amount, timing, and uncertainty of cash flows from leases. ASU 2016-02 is effective for fiscal years and interim periods beginning after December 15, 2018, which for the Company is December 31, 2018, the first day of its 2019 fiscal year. Upon adoption, entities are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. Early adoption is permitted, and a number of optional practical expedients may be elected to simplify the impact of adoption. The Company is currently evaluating the impact of adopting this guidance. The overall impact is that assets and liabilities arising from leases are expected to increase based on the present value of remaining estimated lease payments at the time of adoption. In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting Compensation – Stock Compensation In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842).” Under ASU 2016-02, lessees will, among other things, require lessees to recognize a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. ASU 2016-02 does not significantly change lease accounting requirements applicable to lessors; however, certain changes were made to align, where necessary, lessor accounting with the lessee accounting model and ASC Topic 606, “Revenue from Contracts with Customers.” ASU 2016-02 will be effective for us on January 1, 2019 and initially required transition using a modified retrospective approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. In July 2018, the FASB issued ASU 2018-11 , “Leases (Topic 842) - Targeted Improvements,” which, among other things, provides an additional transition method that would allow entities to not apply the guidance in ASU 2016-02 in the comparative periods presented in the financial statements and instead recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. In December 2018, the FASB also issued ASU 2018-20, “Leases (Topic 842) - Narrow-Scope Improvements for Lessors,” which provides for certain policy elections and changes lessor accounting for sales and similar taxes and certain lessor costs. As of January 1, 2019, the Company adopted ASU 2016-02 and has recorded a right-of-use asset and lease liability on the balance sheet for its operating leases. We elected to apply certain practical expedients provided under ASU 2016-02 whereby we will not reassess(i) whether any expired or existing contracts are or contain leases, (ii) the lease classification for any expired or existing leases and (iii) initial direct costs for any existing leases. We also do not expect to apply the recognition requirements of ASU 2016-02 to any short-term leases (as defined by related accounting guidance). We expect to account for lease and non-lease components separately because such amounts are readily determinable under our lease contracts and because we expect this election will result in a lower impact on our balance sheet. In October 2016, the FASB issued ASU 2016-16, “Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other than Inventory”, which eliminates the exception that prohibits the recognition of current and deferred income tax effects for intra-entity transfers of assets other than inventory until the asset has been sold to an outside party. The updated guidance is effective for annual periods beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption of the update is permitted. The Company is currently evaluating the impact of the new standard. In April 2016, the FASB issued ASU No. 2016-10, “Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing” (topic 606). In March 2016, the FASB issued ASU No. 2016-08, “Revenue from Contracts with Customers: Principal versus Agent Considerations (Reporting Revenue Gross versus Net)” (topic 606). These amendments provide additional clarification and implementation guidance on the previously issued ASU 2014-09, “Revenue from Contracts with Customers”. The amendments in ASU 2016-10 provide clarifying guidance on materiality of performance obligations; evaluating distinct performance obligations; treatment of shipping and handling costs; and determining whether an entity’s promise to grant a license provides a customer with either a right to use an entity’s intellectual property or a right to access an entity’s intellectual property. The amendments in ASU 2016-08 clarify how an entity should identify the specified good or service for the principal versus agent evaluation and how it should apply the control principle to certain types of arrangements. The adoption of ASU 2016-10 and ASU 2016-08 is to coincide with an entity’s adoption of ASU 2014-09, which we adopted for interim and annual reporting periods beginning after December 15, 2017. The Company is currently evaluating the impact of adopting this guidance. In May 2016, the FASB issued ASU No. 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients”, which narrowly amended the revenue recognition guidance regarding collectability, noncash consideration, presentation of sales tax and transition and is effective during the same period as ASU 2014-09. The Company is currently evaluating the impact of adopting this guidance. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments” (“ASU 2016-15”). ASU 2016-15 will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017. The new standard will require adoption on a retrospective basis unless it is impracticable to apply, in which case it would be required to apply the amendments prospectively as of the earliest date practicable. The Company is currently evaluating the impact of adopting this guidance. In October 2016, the FASB issued ASU 2016-16, “Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other than Inventory”, which eliminates the exception that prohibits the recognition of current and deferred income tax effects for intra-entity transfers of assets other than inventory until the asset has been sold to an outside party. The updated guidance is effective for annual periods beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption of the update is permitted. The Company is currently evaluating the impact of the new standard. In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230)”, requiring that the statement of cash flows explain the change in the total cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. This guidance is effective for fiscal years, and interim reporting periods therein, beginning after December 15, 2017 with early adoption permitted. The provisions of this guidance are to be applied using a retrospective approach which requires application of the guidance for all periods presented. The Company is currently evaluating the impact of adopting this guidance. In July 2017, the FASB issued ASU 2017-11, “Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception”. Part I of this update addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. Part II of this update addresses the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable noncontrolling interests. The amendments in Part II of this update do not have an accounting effect. This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. The Company is currently evaluating the impact of adopting this guidance. In May 2017, the FASB issued ASU 2017-09, “Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting,” which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The Company is currently evaluating the impact of adopting this guidance. Management does not believe that any recently issued, but not yet effective accounting pronouncements, when adopted, will have a material effect on the accompanying consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Schedule of Fair Value Measurement On a Recurring Basis of Assets and Liabilities	The assets or liabilities’ fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of the relevant assets and liabilities that are measured at fair value on a recurring basis: December 31, 2017 Total Quoted Prices Quoted Prices for Similar Assets or Liabilities in Active Significant Unobservable Inputs Warrant liability 3,528,602 - - 3,528,602 Option liability 299,965 - - 299,965 Derivative liability 113,636,474 - - 113,636,474 Total liabilities $ 117,465,041 $ - $ - $ 117,465,041 December 31, 2016 Total Quoted Prices Quoted Prices Significant Unobservable Inputs Warrant liability 14,430 - - 14,430 Derivative liability 15,635,947 - - 15,635,947 Total liabilities $ 15,650,377 $ - $ - $ 15,650,377
Schedule of Fair Value of Company's Level 3 Financial Liabilities Measured at Fair Value On a Recurring Basis	The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis: For the year ended December 31, 2017 Total January 1, 2017 15,650,377 Initial recognition of conversion feature 7,781,259 Initial recognition of warrant liability 3,277,052 Initial recognition of option liability 299,925 Change in fair value of conversion feature 90,219,268 Change in fair value of warrant liability 237,120 Change in fair value of option liability 40 Ending Balance, December 31, 2017 $ 117,465,041 For the year ended December 31, 2016 Total January 1, 2016 $ 20,186,594 Initial recognition of conversion feature 581,817 Change in fair value of conversion feature 33,271,611 Gain on extinguishment of debt (37,464,075 ) Change in fair value of liability (918,969 ) Unrealized loss on marketable securities (6,601 ) December 31, 2016 15,650,377
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The Company had the following Common Stock equivalents at December 31, 2017 and 2016: December 31, 2017 December 31, 2016 Warrants 11,765,757,748 69,757,748 Options 1,000,000,000 - Convertible notes – related party 10,500,000 10,500,000 Convertible notes 465,782,195,939 114,808,810,010 Totals 478,558,453,687 114,889,067,758
Schedule of Estimated Useful Lives for Significant Property and Equipment	The Company uses accelerated depreciation methods for tax purposes where appropriate. The estimated useful lives for significant property and equipment categories are as follows: Vehicles 5 years Furniture and Fixtures 3 - 5 years Office equipment 3 years Machinery 2 years Buildings 10 - 39 years

Inventory and Capitalized Agr_2

Inventory and Capitalized Agricultural Costs (Tables)	12 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory at December 31, 2017 and 2016 consisted of the following: December 31, 2017 December 31, 2016 Finished goods $ 84,210 $ — Growing crops and biomass 394,903 160,131 Total inventory, net $ 479,113 $ 160,131

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment at December 31, 2017 and 2016 consists of: Property and Equipment December 31, 2017 December 31, 2016 Advances - 472,126 Land 4,945,000 4,945,000 Construction in progress - 1,241,380 Buildings and structures 1,300,630 59,250 Machinery 497,011 21,600 6,742,641 6,739,356 Less accumulated depreciation (397,658 ) (26,988 ) Property and equipment, net $ 6,344,983 $ 6,712,368

Convertible Notes Payable and_2

Convertible Notes Payable and Derivative Liability (Tables)	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	Convertible notes payable consists of: December 31, 2017 December 31, 2016 Investor #1 $ 15,198,404 $ 6,642,745 Investor #2 2,087,198 1,857,146 Investor #3 293,009 231,142 Investor #4 2,462,284 - Investor #5 300,000 - 20,340,895 8,731,033 Less discounts (869,441 ) (85,591 ) Plus premium Less current maturities 19,471,454 8,645,442 Convertible notes payable, net of current maturities $ $

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2017
Schedule of Notes Payable	Notes payable consists of: December 31, 2017 December 31, 2016 Southwest Farms $ 3,536,279 $ 3,590,241 East West Secured Development 486,531 503,031 Investor #1 103,847 3,691,200 Investor #2 - 275,000 Investor #6 65,000 - 4,191,657 8,059,472 Less discounts - (598,721 ) Plus premium - - Subtotal notes payable 4,191,657 7,460,751 Less current maturities 4,191,657 3,367,479 Notes payable, net of current maturities $ - $ 4,093,272
Related Parties [Member]
Schedule of Notes Payable	Notes payable, related parties, consists of: December 31, 2017 December 31, 2016 Notes payable – related parties $ 289,866 $ 289,866 Less discounts — — $ 289,866 $ 289,866

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Schedule of Activity Related to Restricted Stock Units (RSU's)	A summary of the activity related to RSUs for the years ended December 31, 2017 and 2016 is presented below: Restricted stock units (RSUs) Total shares Grant date fair RSUs non-vested at January 1, 2017 7,142,856 $ 0.51 - $1.88 RSUs granted 250,975,000 $ 0.0002 - $0.0003 RSUs vested (258,117,856 ) $ 0.0002 - $1.88 RSUs forfeited - $ - RSUs non-vested December 31, 2017 - $ - Restricted stock units (RSUs) Total shares Grant date fair RSUs non-vested at January 1, 2016 152,823 $ 0.51 - $1.88 RSUs granted 14,285,714 $ 0.007 RSUs vested (7,295,681 ) $ 0.51- $1.88 RSUs forfeited - $ - RSUs non-vested December 31, 2016 7,142,856 $ 0.51 - $1.88
Schedule of Expense Related to Restricted Stock	A summary of the expense related to restricted stock, RSUs and stock option awards for the year ended December 31, 2017 and 2016 is presented below: Year ended RSUs $ 50,293 Stock options 299,925 Total $ 350,218 Year ended RSUs $ 261,196 Common stock 539,246 Total $ 800,442
Schedule of Valuation Assumption	The assumptions used for warrants granted during the year ended December 31, 2017 and 2016 are as follows: December 31, 2017 December 31, 2016 Exercise price $ 5.54 - 0.0001 $ 0.02 Expected dividends 0 % 0 % Expected volatility 284.72% - 249.30 % 289.97 % Risk free interest rate 1.54% - 1.44 % 1.6 % Expected life of warrant 4 years 3 years
Summary of Warrant Activity	The following is a summary of the Company’s warrant activity: Warrants Weighted Average Exercise Price Weighted Average Remaining Days Price Outstanding – December 31, 2015 43,161,222 $ 0.16 $ 2.77 Granted 22,595,859 0.04 3.00 Exercised - - - Forfeited/Cancelled - - - Outstanding – December 31, 2016 65,757,081 0.11 1.97 Granted 11,800,000,000 0.0001 4 Exercised - - - Forfeited/Cancelled (100,000,000 ) 0.001 - Outstanding and Exercisable – December 31, 2017 11,765,757,081 $ 0.0007 $ 3.23
Summary of option Activity	The following is a summary of the Company’s option activity: Warrants Weighted Average Exercise Price Weighted Average Remaining Days Price Outstanding – December 31, 2016 - - - Granted 1,000,000,000 $ 0.0001 5.00 Exercised - - - Forfeited/Cancelled - - - Outstanding and Exercisable – December 31, 2017 1,000,000,000 $ 0.0001 $ 4.59
Schedule of Stock option Granted	The following is a summary of the Company’s stock options granted during the year ended December 31, 2017: Options Value Purpose for Grant 1,000,000,000 $ 299,925 Service Rendered

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2017
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Income (Loss) from Discontinued Operation	The income (loss) from discontinued operations presented in the income statement for the year ended December 31, 2017 and 2016, consisted of the following: For the year ended December 31, 2017 2016 Revenue $ - $ 243,965 Revenue, related party - 99,946 Net revenue - 343,911 Cost of revenues - 99,411 Gross profit (loss) - 244,500 Operating expenses General and administrative 5,171 65,647 Total operating expenses 5,171 65,647 Loss from operations 5,171 178,853 Other income (expense) Interest expense, net (3,221 ) (8,858 ) Gain on sale of assets of subsidiary - 5,498 Loss on sale of rights and assets - (178,833 ) Loss on default settlement of a note - (168,092 ) Other-than-temporary impairment of Marketable securities - (16,010 ) Other income - 141,058 Total other income (expense) (3,221 ) (225,237 ) Net loss $ (8,392 ) $ (46,384 )

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities	Deferred tax assets and liabilities result from temporary differences in the recognition of income and expense for tax and financial reporting purposes. Significant components of the Company’s deferred tax assets and liabilities are as follows at December 31: 2017 2016 Deferred tax assets: $ - $ - Customer deposits - - Deferred revenue - - Share based compensation 631,779 906,214 NOL carryforward 3,375,214 2,469,000 Total deferred tax asset 4,006,993 3,375,214 Deferred tax liabilities: Intangible asset amortization — 4,006,993 3,375,214 Less: Valuation allowance (4,006,993 ) (3,375,214 ) $ - $ -
Schedule of Effective Rate Provision for Income Tax	For the years ended December 31, 2017 and 2016, a reconciliation of the statutory rate and effective rate for the provisions for income taxes consists of the following: 2017 2016 Federal tax statutory rate 34.00 % 34.00 % State tax statutory rate 8.84 % 8.84 % Permanent differences 3.46 % 3.46 % Valuation allowance (46.30 )% (46.30 )% Effective rate 0.00 % 0.00 %

Business Organization, Nature_2

Business Organization, Nature of Operations (Details Narrative)	12 Months Ended
	Dec. 31, 2017aIntegershares	Dec. 31, 2016shares	Apr. 15, 2016shares	Dec. 31, 2015a
Number of operating subsidiaries | Integer	3
Number of common shares authorized (in shares) | shares	10,000,000,000	10,000,000,000	400,000,000
EWSD 1, LLC [Member]
Area of land aquired | a	320			320

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative)	May 24, 2016$ / shares	Dec. 31, 2017USD ($)a	Dec. 31, 2016USD ($)	Dec. 31, 2015a
Net income loss		$ (117,305,354)	$ (17,731,570)
Cash flow from operations		(1,584,213)	(3,552,099)
Working capital		(158,700,000)	(37,700,000)
FDIC insured amount		250,000
Cash equivalents
Allowance of doubtful accounts		0	0
Impairment of inventory		$ 0	$ 32,300
OTC Markets Group, Inc. [Member]
Debt instrument stock price | $ / shares	$ 0.01
Debt instrument stock price, description	On May 24, 2016, the Company received a notice from the OTC Markets Group, Inc. ("OTC Markets") that the Company's bid price was below $0.01 and that the Company did not meet the Standards for Continued Eligibility for OTCQB pursuant to OTC Markets' Standards. If the bid price did not close at or above $0.01 for ten consecutive trading days by November 20, 2016, the Company would be moved to the OTC Pink® Open Market.
EWSD 1, LLC [Member]
Area of land aquired | a		320		320

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Fair Value Measurement on a Recurring Basis of Assets and Liabilities (Details) - Fair Value, Measurements, Recurring [Member] - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities	$ 117,465,041	$ 15,650,377
Warrant Liability [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities	3,528,602	14,430
Option Liability [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities	299,965
Derivative Liability [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities	113,636,474	15,635,947
Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1) [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities
Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1) [Member] | Warrant Liability [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities
Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1) [Member] | Option Liabilities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities
Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1) [Member] | Derivative Liability [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities
Quoted Prices for Similar Assets or Liabilities in Active Markets (Level 2) [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities
Quoted Prices for Similar Assets or Liabilities in Active Markets (Level 2) [Member] | Warrant Liability [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities
Quoted Prices for Similar Assets or Liabilities in Active Markets (Level 2) [Member] | Option Liabilities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities
Quoted Prices for Similar Assets or Liabilities in Active Markets (Level 2) [Member] | Derivative Liability [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities	117,465,041	15,650,377
Significant Unobservable Inputs (Level 3) [Member] | Warrant Liability [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities	3,528,602	14,430
Significant Unobservable Inputs (Level 3) [Member] | Option Liability [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities	299,965
Significant Unobservable Inputs (Level 3) [Member] | Derivative Liability [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities	$ 113,636,474	$ 15,635,947

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Fair Value of Company's Level 3 Financial Liabilities Measured at Fair Value On a Recurring Basis (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Beginning balance	$ 15,650,377	$ 20,186,594
Initial recognition of conversion feature	7,781,259	581,817
Initial recognition of warrant liability	3,277,052
Initial recognition of option liability	299,925
Change in fair value of conversion feature	90,219,268	33,271,611
Change in fair value of warrant liability	237,120	(998,764)
Change in fair value of option liability	40
Gain on extinguishment of debt		(37,464,075)
Change in fair value of liability		(918,969)
Unrealized loss on marketable securities.		(6,601)
Ending Balance	$ 117,465,041	$ 15,650,377

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Totals	478,558,453,687	114,808,810,010
Warrants [Member]
Totals	11,765,757,748	69,757,748
Options [Member]
Totals	1,000,000,000
Convertible Notes - Related Party [Member]
Totals	10,500,000	10,500,000
Convertible Notes [Member]
Totals	465,782,195,939	114,808,810,010

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives for Significant Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2017
Vehicles [Member]
Estimated useful life	5 years
Furniture and Fixtures [Member] | Minimum [Member]
Estimated useful life	3 years
Furniture and Fixtures [Member] | Maximum [Member]
Estimated useful life	5 years
Office Equipment [Member]
Estimated useful life	3 years
Machinery [Member]
Estimated useful life	2 years
Building [Member] | Minimum [Member]
Estimated useful life	10 years
Building [Member] | Maximum [Member]
Estimated useful life	39 years

Asset Acquisition (Details Narr

Asset Acquisition (Details Narrative)	Dec. 18, 2015USD ($)a$ / sharesshares	Dec. 31, 2016$ / shares
Warrants exercisable price | $ / shares		$ 0.02
Growers' Distributor Agreement [Member]
Acquisition date	Sep. 30, 2025
Folium Biosciences LLC [Member] | Farming Agreement [Member]
Area of real estate property	200,000
Gross profits from farming activities	50.00%
Warrant to purchase | shares	4,000,000
Warrants exercisable price | $ / shares	$ 0.50
Warrants exercisable	5 years
Warrants value | $	$ 76,000
Folium Biosciences LLC [Member] | Farming Agreement [Member] | Before September 30, 2017 [Member]
Area of real estate property	10
Folium Biosciences LLC [Member] | Growers' Distributor Agreement [Member]
Area of real estate property	40
East West Secured Development, LLC [Member] | Growers' Distributor Agreement [Member]
Area of real estate property	10

Inventory and Capitalized Agr_3

Inventory and Capitalized Agricultural Costs (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Markdown inventory	$ 0	$ 32,300

Inventory and Capitalized Agr_4

Inventory and Capitalized Agricultural Costs - Schedule of Inventory (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Finished goods	$ 84,210
Growing crops and biomass	394,903	160,131
Total inventory, net	$ 479,113	$ 160,131

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 367,385	$ 17,363

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Advances		$ 472,126
Land	4,945,000	4,945,000
Construction in progress		1,241,380
Buildings and structures	1,300,630	59,250
Machinery	497,011	21,600
Property and equipment, gross	6,742,641	6,739,356
Less accumulated depreciation	(397,658)	(26,988)
Property and equipment, net	$ 6,344,983	$ 6,712,369

PCH Investment (Details Narrati

PCH Investment (Details Narrative) - USD ($)	Dec. 31, 2017	Mar. 21, 2017	Nov. 02, 2016	Dec. 31, 2017	Dec. 14, 2017
Debt instrument, interest rate percentage					6.25%
Debt instrument, description	If Trava converts, in whole or in part, any one or more of such notes, then (unless (i) thereafter, the Company is unable to accommodate any future such conversions because of a lack of authorized, but unissued or unreserved, shares or (ii) the public market price for a share of Common Stock becomes "no bid"), Trava shall continue to exercise its conversion rights in respect of all of such notes (to the 4.9% limitations set forth therein) and shall diligently sell the shares of Common Stock into which any or all of such notes may be converted (collectively, the "Underlying Shares") in open market or other transactions (subject to any limitations imposed by the Federal securities laws and set forth in any "leak-out" type of arrangements in respect of the "underlying shares" to which Trava is a party).
Convertible conversion price per share	$ 0.0001			$ 0.0001
PCH Investment Group, Inc [Member] | PCH Shareholders [Member]
Stock acquired during period		1,500,000,000
Business combination, consideration transferred		$ 300,000
Restated Security and Pledge Agreement [Member] | Maximum [Member]
Value of lending obligation				$ 500,000
PCH Option Agreement [Member] | PCH Investment Group, Inc [Member]
Option agreement, description				Pursuant the PCH Option Agreement, PASE was granted the option to purchase all 49%, but not less than all 49%, of the PCH Optioned Shares. The exercise price for the PCH Optioned Shares is an amount equivalent to five times PCH's "EBITDA" for the 12-calendar month period, on a look-back basis, that concludes on the date of exercise of the Option, less $10.00 (which was the purchase price of the option). The calculation of the 12-month EBITDA was to be determined by PASE's (or its) then-currently engaged independent auditors. If the Company were to exercise the option prior to the first anniversary of the closing of the acquisition of the PCH To-Be-Purchased Shares, then the exercise price for the PCH Optioned Shares was to be based on the EBITDA for the entire 12-calendar month period that commenced with the effective date of the PCH Option Agreement.
Settlement Agreement [Member]
Loss on termination of the PCH transaction				$ 1,001,520
PCH Investment Group, Inc [Member] | PCH Management Agreement [Member]
Gross profit percentage			75.00%
Annual gross profit, milestone			$ 8,000,000
Gross profit milestone method, description			In the event that, during any annual period, the gross profit thereunder was less than $8 million (including any carry-forward amounts), then, on a one- time basis, PCH would have been permitted to carry-forward such deficit to the following annual period. If, in that following annual period, the gross profit was to have exceeded $6 million, then PCH would have been entitled to an additional "one-time basis" carry-forward of a subsequent deficit.
Term of agreement			5 years
PCH Investment Group, Inc [Member]
Business combination, consideration transferred		$ 300,000
Optioned shares expiry date		Feb. 10, 2019
Percentage of purchase price shares equal to stock		15.00%
PCH Investment Group, Inc [Member] | Share-based Compensation Award, Tranche One [Member]
Debt instrument, face value	$ 86,000			86,000
PCH Investment Group, Inc [Member] | Share-based Compensation Award, Tranche One [Member]
Debt instrument, face value	300,000			300,000
PCH Investment Group, Inc [Member] | Share-based Compensation Award, Tranche Three [Member]
Debt instrument, face value	90,000			90,000
PCH Investment Group, Inc [Member] | Share-based Compensation Award, Tranche One [Member]
Debt instrument, face value	170,000			170,000
PCH Investment Group, Inc [Member] | Share-based Compensation Award, Tranche One [Member]
Debt instrument, face value	114,000			114,000
PCH Investment Group, Inc [Member] | Pre-acquisition Loans [Member]
Debt instrument, face value	$ 414,000			$ 414,000
PCH Investment Group, Inc [Member] | PCH Management Agreement [Member] | Maximum [Member]
Annual gross profit, milestone			$ 8,000,000
PCH Investment Group, Inc [Member] | PCH Management Agreement [Member] | Minimum [Member]
Annual gross profit, milestone			$ 6,000,000
PCH Investment Group, Inc [Member] | Convertible Note Purchase Agreement [Member] | Senior Secured Convertible Promissory Note [Member]
Debt instrument, interest rate percentage	10.00%			10.00%
Debt instrument, face value	$ 1,000,000			$ 1,000,000
Debt instrument, description				Principal and interest are subject to certain conversion rights in favor of the PCH Lender. So long as any principal is outstanding or any interest remains accrued, but unpaid, at any time and from time to time, at the option of the PCH Lender, any or all of such amounts may be converted into shares of Common Stock. Notwithstanding such conversion right, and except in the circumstance described in the next sentence, the PCH Lender may not exercise its conversion rights if, in so doing, it would then own more than 4.99% of the Company's issued and outstanding shares of Common Stock. However, upon not less than 61 days' notice, the PCH Lender may increase its limitation percentage to a maximum of 9.99%. The PCH Lender's conversion price is fixed at $0.0001 per share. Principal and accrued interest may be pre-paid from time to time or at any time, subject to 10 days' written notice to the PCH Lender. Any prepayment of principal or interest shall be increased to be at the rate of 130% of the amount so to be prepaid and, during the 10-day notice period, the PCH Lender may exercise its conversion rights in respect of any or all of the amounts otherwise to be prepaid.
Convertible conversion price per share	$ 0.0001			$ 0.0001
PCH Investment Group, Inc [Member] | To be Purchased Shares [Member]
Stock acquired during period		459,999
Acquisition percentage		51.00%
PCH Investment Group, Inc [Member] | PCH Optioned Shares [Member]
Acquisition percentage		49.00%

Convertible Notes Payable and_3

Convertible Notes Payable and Derivative Liability (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 14, 2017	Mar. 15, 2016	Mar. 10, 2016	Mar. 04, 2016
Proceeds from convertible note	$ 2,266,400	$ 3,166,500
Original issue discount	869,441	85,591
Convertible notes payable	$ 20,340,895	8,731,033
Debt interest rate			6.25%
Conversion price per share	$ 0.0001
Gain (loss) on debt extinguishment		29,646,079
Debt conversion, principal amount converted	38,700	12,947,334
Repayments of convertible debt	363,547
Notes payable reclassed to convertible notes payable	$ 4,191,657	$ 7,460,751
Warrant term	4 years	3 years
Exercise price of warrants		$ 0.02
Risk Free Interest [Member]
Warrants and rights outstanding, measurement input, percentage		0.016
Expected Volatility [Member]
Warrants and rights outstanding, measurement input, percentage		2.8997
Investor #1 [Member]
Convertible notes payable	$ 3,691,199
Debt interest rate	24.00%
Investor #1 [Member] | Third Party Lenders [Member] | Debt Conversion One [Member]
Debt conversion, principal amount converted		$ 802,926
Debt conversion, shares issued		4,374,651,437
Investor #1 [Member] | Third Party Lenders [Member] | Debt Conversion Two [Member]
Gain (loss) on debt extinguishment		$ 36,071,697
Debt conversion, principal amount converted		5,188,643
Debt conversion, interest amount converted		686,827
Investor #2 [Member]
Convertible notes payable	$ 275,000
Debt interest rate	24.00%
30 Convertible Notes [Member] | Investor #1 [Member] | Third Party Lenders [Member]
Principal amount		9,700,170
Proceeds from convertible note		2,695,000
Original issue discount		119,737
Advancements on fixed assets paid by lender		161,401
Convertible notes payable		$ 6,818,744
Debt interest rate		10.00%
Debt maturity description		Mature with interest and principal both due between July 13, 2016 through September 9, 2017
Conversion price per share		$ 0.75
Debt conversion description		The convertible notes convert at a fixed rate of $0.75 or a 49% to 40% discount with a lookback of 30 trading days
Derivative liability		$ 12,259,532
Debt discount		1,952,380
Gain (loss) on debt extinguishment		10,307,152
29 Convertible Notes [Member] | Investor #1 [Member] | Third Party Lenders [Member]
Principal amount	$ 1,529,297
Proceeds from convertible note	$ 1,066,400
Debt interest rate	10.00%
Debt maturity description	Mature with interest and principal both due between February 3, 2017 through December 4, 2018
Conversion price per share	$ 0.0001
Debt conversion description	The notes convert at a fixed rate of $0.0001 or a 50% discount with a lookback of 30 trading days
Derivative liability	$ 2,950,900
Debt discount	1,036,301
PCH Related Note [Member] | Investor #1 [Member] | Third Party Lenders [Member]
Repayments of convertible debt	413,457
Convertible Notes [Member] | Investor #1 [Member]
Convertible notes payable	$ 15,198,404	6,642,745
Convertible Notes [Member] | Investor #1 [Member] | Third Party Lenders [Member]
Debt interest rate	24.00%
Repayments of convertible debt	$ 250,000
Late fee, percentage	18.00%
Debt principal increase, description	Principal increases by 50%-30%.
Interest expense	$ 3,698,710
Interest paid	37,148
Convertible Notes [Member] | Investor #2 [Member]
Convertible notes payable	$ 2,087,198	1,857,146
Convertible Notes [Member] | Investor #2 [Member] | Third Party Lenders [Member]
Debt interest rate	24.00%
Debt conversion, principal amount converted	$ 1,935	$ 1,450,661
Debt conversion, shares issued	38,700,000	4,949,130,904
Debt conversion, interest amount converted		$ 38,002
Late fee, percentage	18.00%
Notes payable reclassed to convertible notes payable	$ 275,000
Derivative expense	549,535
Convertible Notes [Member] | Investor #3 [Member]
Convertible notes payable	293,009	231,142
Convertible Notes [Member] | Investor #3 [Member] | Third Party Lenders [Member]
Debt conversion, principal amount converted		$ 51,358
Debt conversion, shares issued		205,431,250
Convertible Notes [Member] | Investor #4 [Member]
Convertible notes payable	$ 2,462,284
Convertible Notes [Member] | Investor #4 [Member] | Third Party Lenders [Member]
Debt interest rate	24.00%
Late fee, percentage	18.00%
Interest expense	$ 820,761
Debt principal increase, percentage	50.00%
Convertible Notes [Member] | Investor #5 [Member]
Convertible notes payable	$ 300,000
Convertible Notes [Member] | Investor #5 [Member] | Third Party Lenders [Member]
Debt interest rate	24.00%
Late fee, percentage	18.00%
Interest expense	$ 100,000
Debt principal increase, percentage	50.00%
18 Convertible Notes [Member] | Investor #1 [Member]
Principal amount		3,691,199
Proceeds from convertible note		1,095,741
Original issue discount		$ 996,199
Debt maturity description		Due between December 12, 2016 through November 18, 2017
Conversion price per share		$ 0.75
18 Convertible Notes [Member] | Investor #1 [Member] | Third Party Lenders [Member]
Notes payable reclassed to convertible notes payable	$ 3,691,199
18 Convertible Notes [Member] | Investor #4 [Member]
Derivative liability	390,967
Interest expense	328,116
2 Convertible Notes [Member] | Investor #2 [Member] | Third Party Lenders [Member]
Principal amount		$ 278,000
Proceeds from convertible note		$ 235,000
Debt interest rate		5.00%
Debt maturity description		Mature with interest and principal both due between July 13, 2016 through April 30, 2017
Conversion price per share		$ 0.75
Debt conversion description		The convertible notes convert at a fixed rate of $0.75 or a 49% discount with a lookback of 20 trading days
Derivative liability		$ 282,312
Debt discount		265,917
Interest expense		16,395
Payment by lendor for vendor liabilities		43,000
2 Convertible Notes [Member] | Investor #3 [Member] | Third Party Lenders [Member]
Principal amount		282,500
Proceeds from convertible note		236,500
Original issue discount		$ 34,750
Debt interest rate		10.00%
Debt maturity description		Mature with interest and principal both due between September 14, 2016 through August 20, 2017
Conversion price per share		$ 0.75
Debt conversion description		Notes are convertible upon default at a rate of $0.75 or a 49% discount with a lookback of 30 trading days
Derivative liability		$ 672,335
Debt discount		332,592
Interest expense		339,743
Payment by lendor for vendor liabilities		$ 11,250
7 Convertible Notes [Member] | Investor #4 [Member] | Third Party Lenders [Member]
Principal amount	1,641,522
Proceeds from convertible note	$ 1,000,000
Debt interest rate	10.00%
Debt maturity description	Mature with interest and principal both due between March 15, 2018 through November 09, 2018
Conversion price per share	$ 0.0001
Debt conversion description	The notes convert at a fixed rate of $0.0001 or a 50% discount with a lookback of 30 trading days
Derivative liability	$ 3,842,628
Debt discount	2,979,231
Payments of farm expenses	$ 641,522
Number of warrants issued to purchase of common stock	10,000,000,000
Purchase price of warrants	$ 0.0001
Warrant term	4 years
2 Convertible Note [Member] | Investor #5 [Member]
Debt discount	$ 29,802
2 Convertible Note [Member] | Investor #5 [Member] | Third Party Lenders [Member]
Principal amount	200,000
Proceeds from convertible note	$ 200,000
Debt interest rate	10.00%
Debt maturity description	Mature with interest and principal both due between April 27, 2018 through May 8, 2018
Conversion price per share	$ 0.0001
Debt conversion description	Notes are convertible upon default at a rate of $0.0001 or a 49% discount with a lookback of 30 trading days
Derivative liability	$ 438,196
Debt discount	$ 170,198
Number of warrants issued to purchase of common stock	200,000
Purchase price of warrants	$ 0.0001
Warrant term	4 years
Subordinated Convertible Promissory Note 1 [Member] | Director One [Member]
Principal amount						$ 25,000
Conversion price per share						$ 0.01
Subordinated Convertible Promissory Note 2 [Member] | Director One [Member]
Principal amount					$ 25,000
Conversion price per share					$ 0.01
Subordinated Convertible Promissory Note 3 [Member] | Director One [Member]
Principal amount				$ 25,000
Conversion price per share				$ 0.01
Subordinated Convertible Promissory Note [Member]
Debt interest rate	8.00%
Debt instrument term	3 years
Subordinated Convertible Promissory Note [Member] | Director One [Member]
Principal amount	$ 75,000
Subordinated Convertible Promissory Note 4 [Member] | Director Two [Member]
Principal amount				$ 25,000
Conversion price per share				$ 0.01
Subordinated Convertible Promissory Note 5 [Member] | Two Directors [Member]
Principal amount				$ 2,500
Conversion price per share				$ 0.01
Board Notes [Member] | Warrants [Member] | Expected Term [Member]
Warrants and rights outstanding, measurement input, term	3 years
Board Notes [Member] | Warrants [Member] | Risk Free Interest [Member]
Warrants and rights outstanding, measurement input, percentage	0.0093
Board Notes [Member] | Warrants [Member] | Expected Volatility [Member]
Warrants and rights outstanding, measurement input, percentage	1.72
Board Notes [Member] | Directors [Member] | Warrants [Member]
Warrant term	3 years
Warrants issued, description	In connection with their funding of the Notes (collectively, the 'Board Notes'), the directors each received a warrant, exercisable for a period of three (3) years from the date of Board Notes, to purchase an amount of Common Stock equal to 50% of the principal sum under each of the Board Notes, at an exercise price equal to 200% of the applicable Conversion Price.
Exercise price of warrants	$ 0.02
Fair value of warrants	$ 42,000

Convertible Notes Payable and_4

Convertible Notes Payable and Derivative Liability - Schedule of Convertible Notes Payable (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Convertible notes payable	$ 20,340,895	$ 8,731,033
Less discounts	(869,441)	(85,591)
Plus premium
Less current maturities	19,471,454	8,645,442
Convertible notes payable, net of current maturities
Investor #1 [Member]
Convertible notes payable	3,691,199
Investor #2 [Member]
Convertible notes payable	275,000
Convertible Notes [Member] | Investor #1 [Member]
Convertible notes payable	15,198,404	6,642,745
Convertible Notes [Member] | Investor #2 [Member]
Convertible notes payable	2,087,198	1,857,146
Convertible Notes [Member] | Investor #3 [Member]
Convertible notes payable	293,009	231,142
Convertible Notes [Member] | Investor #4 [Member]
Convertible notes payable	2,462,284
Convertible Notes [Member] | Investor #5 [Member]
Convertible notes payable	$ 300,000

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	Jul. 31, 2016	Jun. 14, 2016	May 06, 2016	Apr. 21, 2016	Apr. 06, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 14, 2017	Mar. 14, 2016
Proceeds from convertible note						$ 2,266,400	$ 3,166,500
Original issue discount						869,441	85,591
Repayments of notes payable						$ 74,492	509,461
Debt instrument, interest rate percentage								6.25%
Debt convertible default rate						$ 0.0001
Debt discount amount
Conversion notes payable						20,340,895	$ 8,731,033
Warrant exercise price							$ 0.02
Fair valure of warrants						$ 237,120	$ (998,764)
Warrant expected term						4 years	3 years
Risk Free Interest [Member]
Warrants and rights outstanding, measurement input							0.016
Expected Volatility [Member]
Warrants and rights outstanding, measurement input							2.8997
Minimum [Member]
Warrant exercise price						$ 0.0001
Minimum [Member] | Risk Free Interest [Member]
Warrants and rights outstanding, measurement input						0.0154
Minimum [Member] | Expected Volatility [Member]
Warrants and rights outstanding, measurement input						2.8472
Maximum [Member]
Warrant exercise price						$ 5.54
Maximum [Member] | Risk Free Interest [Member]
Warrants and rights outstanding, measurement input						0.0144
Maximum [Member] | Expected Volatility [Member]
Warrants and rights outstanding, measurement input						2.4930
Investor #1 [Member]
Debt instrument, interest rate percentage						24.00%
Conversion notes payable						$ 3,691,199
Investor #2 [Member]
Debt instrument, interest rate percentage						24.00%
Conversion notes payable						$ 275,000
18 Convertible Notes [Member] | Investor #1 [Member]
Debt face amount							$ 3,691,199
Proceeds from convertible note							1,095,741
Original issue discount							996,199
Repayments of notes payable							$ 145,000
Maturity date description							Due between December 12, 2016 through November 18, 2017
Debt convertible default rate							$ 0.75
Debt discount rate							40.00%
18 Convertible Notes [Member] | Investor #1 [Member] | Minimum [Member]
Debt instrument, interest rate percentage							5.00%
18 Convertible Notes [Member] | Investor #1 [Member] | Maximum [Member]
Debt instrument, interest rate percentage							10.00%
18 Convertible Notes [Member] | Investor #4 [Member]
Derivative liability						390,967
Debt discount amount						230,901
Interest expense						328,116
4 Notes [Member] | Investor #1 [Member]
Debt face amount						103,847
Proceeds from convertible note						95,527
Original issue discount						819
Repayments of notes payable						$ 7,500
Maturity date description						These notes mature from May 2017 through August of 2017.
Promissory Note [Member] | Investor #6 [Member]
Settlement and outstanding amount						$ 65,000
Gain of settlement amount						$ 82,776
Promissory Note [Member] | Investor #7 [Member]
Debt face amount					$ 87,500
Debt instrument, interest rate percentage					0.00%
Debt discount amount					$ 2,500
Number of restricted stock issued					600,000
Periodic payments of debt	$ 2,500		$ 20,000	$ 40,000
Final payment of debt			$ 27,500
Additional payment					$ 2,500
Promissory Note [Member] | Director [Member]
Debt face amount		$ 250,700							$ 41,667
Debt instrument, interest rate percentage		8.00%							8.00%
Debt instrument term		6 months
Percentage of warrant issued on face amount		50.00%
Warrant exercise price		$ 0.01
Warrant exercisable period		3 years
Fair valure of warrants		$ 12,000
Debt discount		$ 12,000
Promissory Note [Member] | Director [Member] | Expected Term [Member]
Warrant expected term		3 years
Promissory Note [Member] | Director [Member] | Risk Free Interest [Member]
Warrants and rights outstanding, measurement input		0.0093
Promissory Note [Member] | Director [Member] | Expected Volatility [Member]
Warrants and rights outstanding, measurement input		1.72

Notes Payable - Schedule of Not

Notes Payable - Schedule of Notes Payable (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Notes payable gross	$ 4,191,657	$ 8,059,472
Less discounts		(598,721)
Plus premium
Subtotal notes payable	4,191,657	7,460,751
Less current maturities	4,191,657	3,367,478
Notes payable, net of current maturities		4,093,272
Related Parties [Member]
Notes payable gross	289,866	289,866
Less discounts
Notes payable, related parties	289,866	289,866
Investor #1 [Member]
Notes payable gross	103,847	3,691,200
Investor #2 [Member]
Notes payable gross		275,000
Investor #6 [Member]
Notes payable gross	65,000
Southwest Farms, Inc. [Member]
Notes payable gross	3,536,279	3,590,241
East West Secured Development, LLC [Member]
Notes payable gross	$ 486,531	$ 503,031

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative) - USD ($)	Nov. 26, 2019	Jan. 20, 2017	Jun. 08, 2016	Mar. 31, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2017	Dec. 31, 2016	Apr. 15, 2016
Preferred stock, voting rights								The Series A Preferred Stock has special voting rights when voting as a class with the Common Stock as follows: (i) the holders of Series A Preferred Stock shall have such number of votes as is determined by multiplying (a) the number of shares of Series A Preferred Stock held by such holder, by (b) the number of issued and outstanding shares of the Company's Series A Preferred Stock and Common Stock (collectively, the "Common Stock") on a Fully-Diluted Basis (as hereinafter defined), as of the record date for the vote, or, if no such record date is established, as of the date such vote is taken or any written consent of stockholders is solicited, and by (c) 0.00000025; and (ii) the holders of Common Stock shall have one vote per share of Common Stock held as of such date. "Fully-Diluted Basis" mean that the total number of issued and outstanding shares of Common Stock shall be calculated to include (a) the shares of Common Stock issuable upon exercise and/or conversion of all of the following securities (collectively, "Common Stock Equivalents"): all outstanding (a) securities convertible into or exchangeable for Common Stock, whether or not then convertible or exchangeable (collectively, "Convertible Securities"), (b) subscriptions, rights, options and warrants to purchase shares of Common Stock, whether or not then exercisable (collectively, "Options"), and (c) securities convertible into or exchangeable or exercisable for Options or Convertible Securities and any such underlying Options and/or Convertible Securities.
Preferred stock, shares outstanding								0	0
Common stock, shares authorized								10,000,000,000	10,000,000,000	400,000,000
Value of shares sold, common stock									$ 16,000
Number of shares sold, common stock									851,063
Value of shares issued for service render									$ 96,790
Contributed related party, shares									324,754
Number shares investor cancelled in derivative settlements									1,633,652
Number of shares authorized for grants					2,761,000
Stock compensation expense					$ 13,000			$ 299,925	$ 0
Aggregate intrinsic value of warrants outstanding								2,340,000
Aggregate intrinsic value of warrants exercisable								$ 1,340,000
Warrants exercised
Change in fair value of warrant liability								$ 237,120	$ (998,764)
Aggregate intrinsic value of options outstanding								200,000	200,000
Aggregate intrinsic value of options exercisable								$ 0	$ 0
Convertible Note Payable [Member]
Warrants outstandinig, shares								10,200,000,000
Change in fair value of warrant liability								$ 3,009,034
2014 Equity Incentive Plan [Member]
Number of shares available for grant			125,000,000
Director [Member]
Number of shares issued for compensation						975,000	325,000	17,076,132
Value of shares issued for compensation						$ 9,750	$ 15,000	$ 50,098
Consultants [Member]
Number of shares issued for service rendered									144,042,308
Value of shares issued for service render									$ 96,790
Employees [Member]
Number of shares issued for service rendered									28,778,831
Value of shares issued for service render									$ 809,424
Chairman [Member]
Number of shares issued for service rendered			6,027,000			2,230,000
Value of shares issued for service render			$ 8,000
Cash bonus awarded			$ 89,200	$ 89,000
Subsequent Event [Member]
Number of common stock, shares issued	9,982,923,868
Common Stock [Member]
Number of common stock, shares issued									851,063
Number of shares issued for service rendered									144,042,308
Value of shares issued for service render									$ 144,042
Common Stock [Member] | Crystal v. Medbox, Inc [Member]
Number of common stock, shares issued		2,000,000
Warrants [Member]
Number of shares issued for service rendered								1,600,000,000
Warrants outstandinig, shares								11,765,757,081
Warrant black scholes description								The fair value of these warrants was re-measured on December 31, 2017 using the Black-Scholes-Merton model, with key valuation assumptions used that consist of the price of the Company's stock on December 31, 2017, a risk-free interest rate based on the average yield of a 1 or 4 year Treasury note and expected volatility of shares of Common Stock, resulting in the fair value for the Warrant liability of approximately $3,528,602.
Change in fair value of warrant liability								$ 3,528,602
Number of shares vested, warrants								5,000,000,000
Vesting revenue								$ 12,000,000
Warrants [Member]
Change in fair value of warrant liability								$ 268,018
Series A Preferred Stock [Member]
Preferred stock, shares outstanding

Stockholders' Deficit - Schedul

Stockholders' Deficit - Schedule of Activity Related to Restricted Stock Units (RSU's) (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
RSUs non-vested, beginning balance	7,142,856	152,823
RSUs granted	250,975,000	14,285,714
RSUs vested	(258,117,856)	(7,295,681)
RSUs forfeited
RSUs non-vested, ending balance		7,142,856
RSUs Grant date fair value, granted		$ 0.007
RSUs Grant date fair value, forfeited
RSUs non-vested Grant date fair value, ending balance
Minimum [Member]
RSUs non-vested Grant date fair value, beginning balance	0.51	0.51
RSUs Grant date fair value, granted	0.0002
RSUs Grant date fair value, vested	0.0002	0.51
RSUs non-vested Grant date fair value, ending balance		0.51
Maximum [Member]
RSUs non-vested Grant date fair value, beginning balance	1.88	1.88
RSUs Grant date fair value, granted	0.0003
RSUs Grant date fair value, vested	$ 1.88	1.88
RSUs non-vested Grant date fair value, ending balance		$ 1.88

Stockholders' Deficit - Sched_2

Stockholders' Deficit - Schedule of Expense Related to Restricted Stock (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share based compensation	$ 631,777	$ 906,214
Restricted Stock Units (RSUs) [Member]
Share based compensation	50,293	261,196
Stock Option [Member]
Share based compensation	299,925
Restricted Stock, RSUs and Stock Option Awards [Member]
Share based compensation	$ 350,218	800,442
Common Stock [Member]
Share based compensation		$ 539,246

Stockholders' Deficit - Sched_3

Stockholders' Deficit - Schedule of Valuation Assumption (Details)	Dec. 31, 2017$ / shares	Dec. 31, 2016$ / shares
Warrant exercise price		$ 0.02
Warrants and rights outstanding, term	4 years	3 years
Measurement Input, Expected Dividend Rate [Member]
Warrants and rights outstanding, measurement input	0	0
Expected Volatility [Member]
Warrants and rights outstanding, measurement input		2.8997
Risk Free Interest [Member]
Warrants and rights outstanding, measurement input		0.016
Minimum [Member]
Warrant exercise price	$ 0.0001
Minimum [Member] | Expected Volatility [Member]
Warrants and rights outstanding, measurement input	2.8472
Minimum [Member] | Risk Free Interest [Member]
Warrants and rights outstanding, measurement input	0.0154
Maximum [Member]
Warrant exercise price	$ 5.54
Maximum [Member] | Expected Volatility [Member]
Warrants and rights outstanding, measurement input	2.4930
Maximum [Member] | Risk Free Interest [Member]
Warrants and rights outstanding, measurement input	0.0144

Stockholders' Deficit - Summary

Stockholders' Deficit - Summary of Warrant Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Equity [Abstract]
Warrants outstanding, beginning balance	65,757,081	43,161,222
Warrants granted	11,800,000,000	22,595,859
Warrants exercised
Warrants forfeited/cancelled	(100,000,000)
Warrants outstanding, ending balance	11,765,757,081	65,757,081
Weighted average exercise price outstanding,beginning balance	$ 0.11	$ 0.16
Weighted average exercise price, granted	0.0001	0.04
Weighted average exercise price, exercised
Weighted average exercise price, forfeited/cancelled	0.001
Weighted average exercise price outstanding, ending balance	0.0007	0.11
Weighted average remaining days price outstanding, beginning balance	1.97	2.77
Weighted average remaining days price, granted	4	3
Weighted average remaining days price, exercised
Weighted average remaining days price, forfeited/cancelled
Weighted average remaining days price outstanding, ending balance	$ 3.23	$ 1.97

Stockholders' Deficit - Summa_2

Stockholders' Deficit - Summary of Option Activity (Details)	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Equity [Abstract]
Number of Shares Options Outstanding and Exercisable Ending Balance | shares
Number of Options Granted | shares	1,000,000,000
Number of Options Exercised | shares
Number of Options Forfeited/cancelled | shares
Number of Shares Options Outstanding and Exercisable Ending Balance | shares	1,000,000,000
Weighted Average Exercise Price Outstanding and Exercisable Ending Balance
Weighted Average Exercise Price Granted	0.0001
Weighted Average Exercise Price Exercised
Weighted Average Exercise Price Forfeited/cancelled
Weighted Average Exercise Price Outstanding and Exercisable Ending Balance	0.0001
Weighted Average Remaining Days Price Outstanding and Exercisable Ending Balance
Weighted Average Remaining Days Price Granted	5
Weighted Average Remaining Days Price Exercised
Weighted Average Remaining Days Price Forfeited/cancelled
Weighted Average Remaining Days Price Outstanding and Exercisable Ending Balance	$ 4.59

Stockholders' Deficit - Sched_4

Stockholders' Deficit - Schedule of Stock Option Granted (Details)	12 Months Ended
	Dec. 31, 2017USD ($)shares
Equity [Abstract]
Stock options granted, service rendered, shares | shares	1,000,000,000
Stock options granted, service rendered, value | $	$ 299,925

Related Party Transactions (Det

Related Party Transactions (Details Narrative)	Mar. 31, 2016USD ($)
Three Convertible Notes [Member] | Director [Member]
Principal amount	$ 75,000
Convertible Note [Member] | Director [Member]
Principal amount	25,000
Convertible Note [Member] | Director One [Member]
Principal amount	2,500
Convertible Note [Member] | Director Two [Member]
Principal amount	$ 2,500

Discontinued Operations (Detail

Discontinued Operations (Details Narrative) - USD ($)	Mar. 28, 2016	Dec. 31, 2017	Dec. 31, 2016
Discontinued Operations and Disposal Groups [Abstract]
Sale of assets	$ 70,000	$ 2,492	$ 2,522
Disposal interest rate, description	80 percent interest in one of two product lines that account for 40 percent of total revenue

Discontinued Operations - Sched

Discontinued Operations - Schedule of Income (Loss) from Discontinued Operation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Discontinued Operations and Disposal Groups [Abstract]
Revenue		$ 243,965
Revenue, related party		99,946
Net revenue		343,911
Cost of revenues		99,411
Gross profit (loss)		244,500
General and administrative	5,171	65,647
Total operating expenses	5,171	65,647
Loss from operations	5,171	178,853
Interest expense, net	(3,221)	(8,858)
Gain on sale of assets of subsidiary		5,498
Loss on sale of rights and assets		(178,833)
Loss on default settlement of a note		(168,092)
Other-than-temporary impairment of Marketable securities		(16,010)
Other income		141,058
Total other income (expense)	(3,221)	(225,237)
Net loss	$ (8,392)	$ (46,384)

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	12 Months Ended
	Dec. 31, 2017USD ($)
Income Tax Disclosure [Abstract]
Decrease in valuation allowance	$ (4,006,993)

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Customer deposits
Deferred revenue
Share based compensation	631,779	906,214
NOL carryforward	3,375,214	2,469,000
Total deferred tax asset	4,006,993	3,375,214
Intangible asset amortization
Total deferred tax liabilities	4,006,993	3,375,214
Less: Valuation allowance	(4,006,993)	(3,375,214)
Total deferred tax

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Rate Provision for Income Tax (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Federal tax statutory rate	34.00%	34.00%
State tax statutory rate	8.84%	8.84%
Permanent differences	3.46%	3.46%
Valuation allowance	(46.30%)	(46.30%)
Effective rate	0.00%	0.00%

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)

Nov. 26, 2019shares

Mar. 31, 2019USD ($)

Jun. 25, 2018USD ($)

Jan. 29, 2018

Dec. 31, 2017USD ($)$ / shares

Dec. 14, 2017USD ($)

Nov. 30, 2017USD ($)

Aug. 23, 2017USD ($)

May 31, 2017

Sep. 16, 2016USD ($)

Sep. 08, 2016USD ($)

Aug. 31, 2016USD ($)

Jun. 17, 2016USD ($)a

May 30, 2016USD ($)

Mar. 01, 2016USD ($)shares

Aug. 01, 2011USD ($)

Jan. 31, 2017USD ($)

Nov. 30, 2016USD ($)

Jan. 31, 2016USD ($)

Dec. 31, 2017USD ($)$ / sharesshares

Dec. 31, 2016USD ($)

Jan. 25, 2019a

May 17, 2018USD ($)

Oct. 27, 2017USD ($)

May 22, 2013USD ($)

Rent expenses

$ 46,522

$ 20,474

$ 89,000

Litigation damages awarded

$ 374,402

$ 300,000

Compensation cost per month

$ 15,000

Payment of common stock

5,000

16,000

Litigation settlement

$ 89,000

$ 374,402

Debt instrument, interest rate percentage

6.25%

Cash payment to a settlement

$ 1,850,000

Number of shares issued for settlement escrow account | shares

2,300,000

Payment in settlement of escrow account

$ 300,000

Capitalized agricultural costs

$ 394,903

$ 394,903

$ 160,131

Litigation payment, description

On March 16, 2017, the Company and Mani Brothers agree to settle the amount owed if the Company paid $40,000 before July 2017. The Company paid the $40,000 in four monthly payments commencing in April 2017. On July 24, 2017, the case was dismissed against the Company.

Debt description

If Trava converts, in whole or in part, any one or more of such notes, then (unless (i) thereafter, the Company is unable to accommodate any future such conversions because of a lack of authorized, but unissued or unreserved, shares or (ii) the public market price for a share of Common Stock becomes "no bid"), Trava shall continue to exercise its conversion rights in respect of all of such notes (to the 4.9% limitations set forth therein) and shall diligently sell the shares of Common Stock into which any or all of such notes may be converted (collectively, the "Underlying Shares") in open market or other transactions (subject to any limitations imposed by the Federal securities laws and set forth in any "leak-out" type of arrangements in respect of the "underlying shares" to which Trava is a party).

Convertible conversion price per share | $ / shares

$ 0.0001

$ 0.0001

Subsequent Event [Member]

Area of land | a

1,840

Number of common stock issuable | shares

9,982,923,868

Whole Hemp Plants [Member]

Capitalized agricultural costs

$ 73,345

$ 73,345

Notis Global, Inc.[Member]

Cash payment to a settlement

$ 150,000

Number of shares issued for settlement escrow account | shares

2,000,000

Insurers [Member]

Cash payment to a settlement

$ 1,700,000

Bruce Bedrick [Member]

Number of shares issued for settlement escrow account | shares

300,000

Messrs. Mehdizadeh [Member]

Number of shares issued for settlement escrow account | shares

2,000,000

Bedrick [Member]

Number of shares issued for settlement escrow account | shares

300,000

Plaintiff Merritts [Member]

Litigation settlement

$ 135,000

Bank Leumi [Member]

Litigation damages awarded

$ 29,977

MedVend Holdings LLC [Member]

Ownership percentage

50.00%

Investment owned

$ 4,100,000

Creaxion Corporation [Member]

Litigation settlement

$ 89,000

Default judgement value

$ 89,000

$ 89,000

Pre judgement interest rate, percentage

6.25%

Sheppard, Mullin, Richter & Hampton LLP [Member]

Breach of contract, value

$ 240,000

Sheppard, Mullin, Richter & Hampton LLP [Member] | Subsequent Event [Member]

Default judgement value

$ 277,999

Sheppard, Mullin, Richter & Hampton LLP [Member] | Subsequent Event [Member] | Due on June 29, 2018 [Member]

Litigation settlement

$ 50,000

Sheppard, Mullin, Richter & Hampton LLP [Member] | Subsequent Event [Member] | Due on June 28, 2019 [Member]

Litigation settlement

$ 25,000

Acquisition Agreement [Member]

Area of land | a

116

Purchase price to acquire property

$ 650,000

Escrow deposit

$ 10,000

Lease Agreement [Member]

Rent expenses

$ 7,486

Sublease term

18 months

Lease Agreement [Member] | West Hollywood, California [Member]

Rent expenses

$ 14,828

Consulting Agreement [Member]

Compensation cost per month

25,000

$ 3,500

Payment of common stock

$ 5,000

Number of common stock issuable | shares

1,500,000

Consulting Agreement [Member] | Shares Tranches [Member]

Number of common stock issuable | shares

375,000

Settlement Agreement [Member] | Three Shareholders [Member]

Litigation settlement

$ 375,000

Pueblo Farm - Management Services Agreement [Member]

Debt description

The MS Agreement has a 36-month term with two consecutive 12-month unilateral options exercisable in the sole discretion of Trava. Pursuant to the provisions of the MS Agreement, Trava shall collect all revenue generated by the Pueblo Farm operations. Further, Trava is to satisfy all of the Pueblo Farm-related past due expenses and, subject to certain limitations, to pay all current and future operational expenses of the Pueblo Farm operations. Finally, commencing October 2017, Trava is obligated to make the monthly mortgage payments on the Pueblo Farm, although the Company remains responsible for any and all "balloon payments" due under the mortgage. On a cumulative calendar monthly cash-on-cash basis, Trava is obligated to tender to the Company or, at the Company's option, to either or both of those subsidiaries, an amount equivalent to 51% of the net cash for each such calendar month. Such monthly payments are on the 10th calendar day following the end of a calendar month for which such tender is required. At the end of the five-year term (assuming the exercise by Trava of each of the two above-referenced options), Trava has the unilateral right to purchase the Pueblo Farm operation at a four times multiple of its EBITDA (calculated at the mean average thereof for each of the two option years).

Pueblo Farm - Management Services Agreement [Member] | Subsequent Event [Member]

Agreement description

In connection with the termination of the MS Agreement and in lieu of any compensation and reimbursement that otherwise was to have been tendered by Trava, the parties agreed that, on or before March 31, 2019, the Company would tender to Trava the sum of not less than $250,000.00, subject to increase depending upon the results of the Farm's 2018 harvest season

Termination Agreement [Member] | Subsequent Event [Member]

Tendered value of agreement

$ 265,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)

Nov. 26, 2019shares

Oct. 26, 2019USD ($)

Jul. 31, 2019USD ($)

Jul. 22, 2019USD ($)

Jul. 11, 2019USD ($)shares

May 31, 2019USD ($)

May 10, 2019

May 01, 2019USD ($)a

Mar. 29, 2019USD ($)aInteger

Jan. 25, 2019USD ($)a

Nov. 19, 2018USD ($)

Jun. 20, 2018

Mar. 12, 2018USD ($)a

Jan. 29, 2018USD ($)a

May 30, 2016USD ($)

Jul. 31, 2019USD ($)

Dec. 31, 2016USD ($)

Aug. 22, 2019USD ($)

Dec. 31, 2017

Dec. 14, 2017

Debt instrument, interest rate

6.25%

Number of common stock shares issued, value

$ 5,000

$ 16,000

Investor #2 [Member]

Debt instrument, interest rate

24.00%

Subsequent Event [Member]

Operating lease term

7 years

Area of land | a

1,840

Monthly rent expense

$ 1,200

Minimum monthly lease payments

$ 3,000

Lease description

The commencement date of this agreement was May 1, 2019; currently, the Company is operating out of a temporary space while the full space is prepared. The monthly rent is $1,200 for the temporary space which ends August 30, 2019.

Number of common stock, shares issued | shares

9,982,923,868

Subsequent Event [Member] | Aeon Funds, LLC [Member]

Agreement description

In consideration for the services provided, Shi Farms has agreed to pay Aeon Capital a cash fee of up to 10% of the gross proceeds from the sale of units to investors introduced by Aeon Capital, and 2.5% of the gross proceeds from the sale of units to investors introduced by the Company.

Preferred membership units

$ 3,915,000

Cash fees paid

$ 193,490

Subsequent Event [Member] | Joint Venture Agreement [Member] | Canbiola Sub [Member]

Payments to joint venture

$ 500,000

Number of common stock shares issued, value

$ 500,000

Number of common stock, shares issued | shares

12,074,089

Percentage of gross profit

70.00%

Subsequent Event [Member] | Joint Venture Agreement [Member] | NY - SHI, LLC [Member]

Percentage of gross profit

30.00%

Subsequent Event [Member] | March 2018 Aeon Agreement [Member] | Aeon Funds, LLC [Member]

Repayments of debt

$ 1,374,893

Area of land | a

100

Number of common stock shares issued, value

$ 1,000,000

$ 100,000

$ 100,000

Investments

$ 1,000,000

Agreement description

Shi Farms will pay royalties to Aeon in an amount equal to 50% of gross sales of product from the 2018-2019 Crop until the principal investment is fully repaid. Shi Farms will then pay 20% of gross sales of the 2018-2019 Crop to Aeon until gross sales equal $10 million. Once gross sales exceed $10 million, Shi Farms will pay Aeon 10% of gross sales.

Subsequent Event [Member] | March 2018 Aeon Agreement [Member] | Aeon Funds, LLC [Member] | Principal Investment Fully Repaid [Member]

Percentage of gross profit

50.00%

Subsequent Event [Member] | March 2018 Aeon Agreement [Member] | Aeon Funds, LLC [Member] | Gross Sales Equal $10 Million [Member]

Percentage of gross profit

20.00%

Subsequent Event [Member] | March 2018 Aeon Agreement [Member] | Aeon Funds, LLC [Member] | Gross Sales Exceeds $10 Million [Member]

Percentage of gross profit

10.00%

Subsequent Event [Member] | RS Agreement [Member] | NY - SHI, LLC [Member]

Received funding amount

$ 2,854,775

Subsequent Event [Member] | RS Agreement [Member] | AAG Harvest 2019, LLC [Member]

Area of land | a

1,200

Percentage of gross profit

25.00%

Agreement description

In exchange for the investment, AAG Harvest will receive payments equal to 25% of Shi Farms' gross sales of the 2019 Crop until AAG Harvest has received an amount equivalent to the amount of capital raised by AAG Harvest to fund the Funding (approximately 118% of the Funding). After AAG Harvest has received this amount, Shi Farms will pay 12.5% of gross sales of the 2019 Crop to AAG Harvest.

Maximum funding amount

$ 3,910,000

Increase in funding amount

$ 7,100,000

Subsequent Event [Member] | Shi Farms Biomass Joint Venture Agreement [Member]

Percentage of gross profit

87.50%

Cultivation cost, value

$ 1,890,000

Subsequent Event [Member] | Shi Farms Biomass Joint Venture Agreement [Member] | Expected to be Less Based on the Growing Season [Member] | Maximum [Member]

Cultivation cost, value

$ 150,000

Subsequent Event [Member] | Partner Farm Agreement [Member]

Agreement description

Mile High has also agreed to provide Shi Farms with priority processing services for the Product specified in the Partner Farm Agreement, of up to 25% of the production capacity of the processing facilities operated by Mile High on the Farm. The Partner Farm Agreement will have an initial term of five years and shall renew automatically thereafter for one-year increments and is terminable by either Mile High or Shi Farms upon 60 days' written notice. Shi Farms will receive 20% of all sales of the Product and Mile High will receive 80% of the sales price, subject to the payment schedule and terms attached thereto.

Subsequent Event [Member] | Partner Farm Agreement [Member] | NY - SHI, LLC [Member]

Percentage of gross profit

20.00%

Subsequent Event [Member] | Partner Farm Agreement [Member] | Mile High Labs, Inc [Member]

Percentage of gross profit

80.00%

Subsequent Event [Member] | Indivudual Consultant [Member] | Shi Farms Amendment to Joint Venture Agreement [Member]

Area of land | a

98

Agreement description

The term of the agreement commenced, when executed on January 29, 2018, and is to continue through November 4, 2020 (the expiration date of the original, pre-amended joint venture agreement).

Subsequent Event [Member] | Indivudual Consultant [Member] | Shi Farms Amendment to Joint Venture Agreement [Member] | Payment In Cash [Member]

Payments to joint venture

$ 75,000

Subsequent Event [Member] | Indivudual Consultant [Member] | Shi Farms Amendment to Joint Venture Agreement [Member] | Payment in Clone Credits [Member]

Payments to joint venture

25,000

Subsequent Event [Member] | Indivudual Consultant [Member] | Shi Farms Amendment to Joint Venture Agreement [Member] | 1 to 50 Acres [Member] | Minimum [Member]

Base compensation amount, total

100,000

Subsequent Event [Member] | Indivudual Consultant [Member] | Shi Farms Amendment to Joint Venture Agreement [Member] | 151-200 Acres [Member] | Maximum [Member]

Base compensation amount, total

$ 200,000

Subsequent Event [Member] | Two Individuals [Member] | Shi Farms Biomass Joint Venture Agreement [Member]

Area of land | a

450

Number of seeds required, per acre | Integer

3,500

Subsequent Event [Member] | Two Individuals [Member] | Shi Farms Biomass Joint Venture Agreement [Member] | Cultivation cost, Per Acre [Member]

Cultivation cost, value

$ 4,200

Subsequent Event [Member] | Consultants [Member] | Shi Farms Biomass Joint Venture Agreement [Member]

Percentage of gross profit

12.50%

Subsequent Event [Member] | 20 Convertible Notes [Member] | Third Party [Member]

Principal amount

$ 2,143,499

Debt instrument, interest rate

10.00%

Debt instrument, maturity date, description

December 2018 through September 2020

Subsequent Event [Member] | 2 Convertible Notes [Member] | Third Party [Member]

Principal amount

$ 200,000

Debt instrument, interest rate

10.00%

Debt instrument, maturity date, description

April 2019 through May 2019

Subsequent Event [Member] | Two Convertible Notes [Member] | Investor #2 [Member]

Principal amount

$ 2,595,895

Repayments of debt

$ 2,350,000

Subsequent Event [Member] | EWSD Secured Note [Member] | Loan Modification Agreement [Member]

Debt maturity date

Aug. 1, 2020

Additional principal payment

$ 250,000